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SUMMARY 
Polarization of hepatocytes is important for the liver to carry out its functions such as bile 
secretion and detoxification. In this context, cell polarity complexes, which are spatially 
segregated at specific membranous domains, define the 3-dimensional orientation of 
hepatocytes. The disturbance of cell polarity in early phases of tumorigenesis is 
associated with the activation of intracellular oncogenic signaling pathways affecting 
tumor initiation and progression. However, if the disturbance of hepatocellular polarity 
participates in the tumor formation and how the dysregulation of polarity factors affect 
hepatocarcinogenesis is poorly understood.  
In order to define relevant cell polarity factors, which may support hepatocellular 
carcinoma (HCC) development, high-dimensional expression array data derived from 
HCC patients were screened for significantly dysregulated cell polarity genes. A panel of 
significantly dysregulated factors, including the baso-lateral complex protein Scribble 
(Scrib), correlated with poor patient outcome and tumor recurrence. Scrib overexpression 
in HCC tissues associated with genomics gains of the Scribble gene locus on 
chromosome 8q24.3. The loss of membranous Scrib expression or its cytoplasmic 
enrichment was frequently observed in HCC tissues and HCC cell lines but not in normal 
liver tissues. In order to analyze the biological impact of cytoplasmic Scrib accumulation, 
polarized HCC cell lines (HepG2) stably expressing wildtype Scrib (Scrib
WT
, with 
membrane binding) and a mutated Scrib isoform (Scrib
P305L
, with enforced cytoplasmic 
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enrichment) were generated. In vitro, cytoplasmic ScribP305L reduced the formation of 
canalicular structures and moderately supported cell proliferation. In vivo, hydrodynamic 
gene delivery of Scrib
P305L 
and c-MYC induced elevated liver tumor formation compared 
to Scrib
WT 
and c-MYC co-injection. Importantly, Scrib
P305L
 stimulated HCC cell 
invasiveness, reorganization of actin filaments and overexpression of Rho GTPases. A 
comparative analysis of oncogenic pathways revealed an activation of AKT by Scrib
P305L
, 
which was mediated through the destabilization of negative AKT regulators leucine rich 
repeat protein phosphatase 1 (PHLPP1) and phosphatase and tensin homolog (PTEN). 
Transcriptome analysis detected Scrib
P305L
-dependent upregulation of genes, which were 
associated with cell motility, epithelial-mesenchymal transition (EMT) and extracellular 
matrix (ECM) remodeling. Among these genes, secreted protein acidic and cysteine rich 
(SPARC) was highly induced by cytoplasmic Scrib and facilitates cell invasion 
depending on the AP-1 transcription factor subunits ATF2 and JunB. Lastly a significant 
association between cytoplasmic Scrib, AKT and ATF2 activation/phosphorylation and 
loss of E-cadherin was confirmed in human HCC samples and Scrib
P305L
-induced gene 
signatures were detected in patient subgroups with worse overall survival.   
Taken together, this study illustrates that the overexpression and cytoplasmic enrichment 
of the cell polarity factor Scrib supports HCC development and tumor cell dissemination 
through the induction of distinct molecular mechanisms. These mechanisms include 
activation of the AKT signaling axis and stimulation of AP1-target genes, which are 
critical for the migratory phenotype of HCC cells.  
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ZUSAMMENFASSUNG 
Die drei-dimensionale Ausrichtung bzw. Polarität von Hepatozyten ist von zentraler 
Bedeutung für die Funktion der Leber (z.B. Galleproduktion und Detoxifikation). 
Membranassoziierte Zellpolaritätskomplexe definieren die apikale, laterale und basale 
Region einer Hepatozyte und der Verlust hepatozytärer Polarität ist ein frühes Ereignis in 
der Lebertumorentstehung. Gleichzeitig deuten publizierte Ergebnisse darauf hin, dass 
der Polaritätsverlust epithelialer Zellen sowohl eine tumorinitiierende als auch eine 
progressionsfördernde Wirkung ausüben können. Welche Polaritätsproteine jedoch 
maßgeblich an der Lebertumorentstehung beteiligt sind und wie die Dysregulation dieser 
Faktoren die Tumorentstehung beeinflusst, ist bisher kaum unterricht.  
Zur Identifikation relevanter Polaritätsfaktoren im hepatozellulären Karzinom (HCC) 
wurden hoch-dimensionale Expressionsdaten primärer humaner HCCs und des 
umgebenden gesunden Lebergewebes miteinander verglichen. Hierbei korrelierte die 
Überexpression des basolateralen Proteins Scribble (Scrib) signifikant mit einem 
schlechteren Überleben und frühen Tumorrezidiv von HCC-Patienten. Neben der Scrib-
Überexpression, bedingt durch die Amplifikation des Scribble Gens auf Chromosom 
8q24.2, ist ebenfalls ein Verlust der membranären Lokalisation sowie eine 
zytoplasmatische Anreicherung von Scrib in HCC-Geweben und Tumorzellen zu 
beobachten. Um die biologische Wirkung der zytoplasmatischen Scrib-Anreicherung zu 
analysieren, wurden in der HCC-Zelllinie HepG2 wildtypisches Scrib (Scrib
WT
 mit 
Membranbindung) und mutiertes Scrib (Scrib
P305L
 mit erzwungener zytoplasmatischer 
Anreicherung) stabil exprimiert. In vitro reduzierte zytoplasmatisches ScribP305L die 
Bildung des kanalikulären Netzwerks, was auf eine gestörte Zellpolarität hinweist, und 
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reduziert Zellproliferation. In vivo induzierte die Koexpression von ScribP305L und des 
Onkogens c-MYC mittels hydrodynamischer Injektion eine erhöhte Lebertumorbildung 
im Vergleich zu Mäusen mit Scrib
WT
/c-MYC Koexpression. Vor allem induziert 
Scrib
P305L
 die HCC-Zellinvasivität, die Reorganisation von Aktinfilamenten und die 
Überexpression von motogen-wirkenden Rho-GTPasen. Vergleichende Analysen auf 
zellulären Signalwegen zeigen eine Aktivierung des AKT-Signalweges in Scrib
P305L
-
exprimierenden Zellen, was sich durch eine erhöhte Destabilisierung der AKT-
Regulatoren Leucin-rich Repeat-Protein-Phosphatase 1 (PHLPP1) und Phosphatase and 
Tensin-Homolog (PTEN) erklärt. Mit Hilfe von Transkriptomanalysen konnten 
Scrib
P305L
-abhängige Signaturen identifiziert werden, welche mit Zellmotilität, Epithelial-
mesenchymale Transition (EMT) und dem Remodelling der Extrazellularmatrix (EZM) 
assoziiert sind. Unter diesen Scrib
P305L
-abhängigen Genen befindet sich Secreted Protein 
Acidic and Rich in Cysteine (SPARC), welches die Invasivität von HCC Zellen 
signifikant erhöht und durch die AP-1 Transkriptionsfaktoruntereinheiten ATF2 und 
JunB positiv reguliert wird. In humanen Geweben konnte der Zusammenhang zwischen 
zytoplasmatischem Scrib, der Phosphorylierung von AKT und ATF2 als auch dem 
Verlust von E-Cadherin als EMT-Marker bestätigt werden. Ferner konnte eine 
signifikante Anreicherung von Scrib
P305L
-abhängigen Signaturgenen in HCC-Patienten 
mit schlechter Prognose gezeigt werden.  
Zusammenfassend zeigt diese Studie, dass die Überexpression und die zytoplasmatische 
Anreicherung des Zellpolaritätsfaktors Scrib die HCC-Entwicklung und die 
Tumorprogression durch die Induktion bestimmter molekularer Mechanismen unterstützt. 
Diese Mechanismen umfassen die Aktivierung der AKT-Signalkaskade und die 
Stimulation von AP1-Zielgenen, welche für den Migrationsphänotyp von HCC-Zellen 
von zentraler Bedeutung sind. 
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1 INTRODUCTION 
 
1.1 Liver and Hepatocellular carcinoma (HCC) 
1.1.1 Physiology of the liver 
The liver has very important functions such as secretion of bile acid and salt, metabolism 
(anabolic and catabolic processes) of nutrients, as well as detoxification of toxic compounds [1]. 
The physiological function of the liver is mediated by different cell types. The parenchymal cells 
of the liver and metabolically active cells are hepatocytes (about 60% of all cells); while non-
parenchymal cells in the liver include liver sinusoidal endothelial cells (LSECs), Kupffer cells 
and stellate cells. LSECs separate hepatocytes from blood stream and facilitate the so-called 
porto-central blood flow [1]. Kupffer cells are localized near the LSECs in the sinusoids and act 
as central regulators of immune responses in case of infections. Stellate cells are located in the 
Space of Disse between hepatocytes and LSECs and represent the 'store-house' for vitamin A. In 
addition， they produce extracellular matrix (ECM) material in case of liver damage [2].  
The liver exhibits a specific “plate-like” spatial architecture, with layers of hepatocytes in 
between sinusoidal spaces (Figure 4A). The plasma membrane of hepatocyte forms a branching 
network of “bile canaliculi”, which is the place for the secretion of bile components [3]. The liver 
has a unique blood vessel system, in which 75% of the liver blood supply comes from the 
nutrient-rich venous arm, while hepatic arteries contribute with 25% of oxygenated blood [4]. 
Highly fenestrated LSECs allow a permanent contact of hepatocytes with the blood stream, 
which allows a highly efficient transportation between hepatocytes and blood vessels [5]. 
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Figure 1: Liver lobe near the central area. Scheme shows the liver specific “plate-like” structure near the 
central area of a hepatic lobule. Dark blue arrow illustrates the direction of blood flow from the portal triad to 
the central vein. Red dots show the bile canaliculus network between two adjacent hepatocytes. Figure 
modified from “The two epithelial cell types in the liver” [6]. 
 
1.1.2 Epidemiology and Etiology of HCC 
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. 
Worldwide, HCC is the fifth most common cancer type in men (7.9% of cancers) and seventh 
most common in women (6.5% of cancers) [7]. Its incidence is highest in Africa and Eastern Asia 
with more than 80% of all new HCC cases. In contrast, Northern Europe and United States have a 
lower HCC incidence with less than 5.0 per 100,000 individuals. However recent studies 
illustrated decreased HCC incidence in developing countries and an elevated number of cases in 
developed and industrialized countries [7]. The reasons for this phenomenon are changes in the 
frequency of risk factors in the respective population (e.g. viral infections and virus-independent 
liver diseases; see below). Compared to other malignant tumors, HCC is the third leading cause 
of cancer-related death and the 1-year overall survival rate is below 50% [8]. 
Hepatitis B virus (HBV)/hepatitis C virus (HCV) infections are major risk factors for HCC 
development [9]. About 5% of all people worldwide (around 75% in Asia) exhibit a chronic HBV 
infection. There is evidence showing the mechanistic connection between chronic HBV infection 
and cancer development, and HBV is considered to be causative for more than 50% of HCCs [7]. 
In contrast, 30% of the global HCC cases are due to chronic HCV infection. Compared to HBV, 
HCV is leading to a higher percentage of chronic hepatitis (80%) and liver cirrhosis development 
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(20%) [10]. In countries with low HBV/HCV prevalence such as the United States and Germany, 
alcohol abuse is one key etiological risk factor that may lead to alcohol-induced liver disease 
(ALD) and HCC [11]. In addition, nonalcoholic fatty liver disease (NAFLD) and the 
nonalcoholic steatohepatitis (NASH) represent further important risk factors for the development 
of HCC. NAFLD and NASH may progress to liver cirrhosis in about 5% and eventually tumor 
initiation. Although the relative numbers of HCCs derived from NAFLD is low (about 0.5%), this 
etiology is getting more relevant because of the high prevalence of obesity and diabetes in 
industrialized countries [12]. In addition, autoimmune disorders, cholestatic disorders, inherited 
disorders (e.g. hemochromatosis) and aflatoxin exposure represent further risk factors of 
hepatocarcinogenesis.  
 
1.1.3 Pathogenesis of HCC 
So far it is not yet fully understood how HCC progresses from damaged hepatocytes to advanced 
tumors. However, compared to other solid cancers, HCC has some specific histomorphological 
characteristics, which include the step-wise progression from normal hepatocytes to well-
differentiated and premalignant lesions to poorly differentiated and malignantly transformed 
HCC cells [13]. Another important feature of hepatocarcinogenesis is the formation of multiple 
tumors, which might arise from independent tumor initiating events or satellite nodules due to 
intrahepatic metastasis. Especially intrahepatic metastasis is considered to be more aggressive 
resulting in poor patient prognosis [14]. In addition, HCC shows aberrant vascularization, which 
further supports the aggressiveness of tumors [15].  
With regard to molecular pathogenesis, the accumulation of genomic alterations plays an 
important role in the development and progression of HCC. Classification approaches based on 
transcriptome analysis and sequencing data revealed a clear association between distinct genomic 
alteration patterns with biological and clinical features of HCCs [16]. For example, a subgroup of 
HCCs that was characterized by high tumor invasiveness, showed higher HBV copy numbers, 
mutations of the tumor-suppressor gene TP53 mutation, phosphoinositide-3-kinase (PI3K)/AKT 
activation, and rare PI3K catalytic alpha (PIK3CA) mutations. Another subgroup with 
intrahepatic metastasis associated with reduced expression of E-cadherin and activation of the 
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wingless (Wnt) signaling pathway [16]. In addition, chromosome instability and dysregulation of 
DNA methylation have also been described to be involved in the pathogenesis of HCC [17, 18]. 
The tumor microenvironment is another important parameter affecting HCC progression. During 
liver fibrosis and cirrhosis under continuous inflammation, fibrotic stromal cells (so-called 
myofibroblasts) increase the production of secreted factors such as urokinase and matrix 
metalloproteinases (MMPs), which directly affect ECM composition. On the other hand, 
malignantly-transformed tumor cells gain properties of mesenchymal cells, with an abnormal 
production of these secreted factors, which leads to a degradation of basal lamina and increased 
invasion/metastasis of tumor cells [19]. In addition, cytokines and chemokines secreted by non-
parenchymal cells, such as tumor necrosis factor (TNF), interleukin-6 (IL-6), transforming 
growth factor (TGF), accelerate the process of liver fibrosis and are critical for the induction of 
HCC invasiveness [2].  
1.1.4 Treatment for HCC  
So far, surgical resection followed by liver transplantation, which improves the five-year survival 
from 15.2% to 77.2%, represents the only curative treatment for HCC patients. However, the 
treatment is limited to patients with early tumor stages (according to the TNM staging system) 
and good residual liver function (Child-Pugh score). Surgical resection and liver transplantation 
do not improve prognosis of late-stage patients with multiple nodules (>3), metastasis or severe 
liver dysfunction due to cirrhosis [20]. For patients with intermediate or advanced tumor stages, 
only palliative treatment can be offered. HCC must be considered as a chemoresistant tumor 
since neither doxorubicin alone nor combinations of doxorubicin, cisplatin, interferon and 5-
fluorouracil or any other clinically established cytotoxic substances significantly improve 
patient's survival [21].   
Some other therapeutic approaches have been developed for HCC patients with un-respectable 
lesions. For example, transarterial chemoembolization (TACE) treatment was established due to 
the aberrant vascularization of HCC [10]. TACE combines inhibition of tumor blood supply with 
regional delivery of chemotherapy, which shows promising effects on tumor regression and is 
used for intermediate-stage patients and down-staging treatment for surgical resection [22]. In 
addition, the small tyrosine protein kinase inhibitor Sorafenib targets multiple receptors 
regulating pathway in tumor cells and endothelial cells including vascular endothelial growth 
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factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). By this, 
Sorafenib not only affects tumor cell biology but also inhibits angiogenesis in a multi-modal 
manner. Although, first results illustrated that Sorafenib increase the overall survival of HCC 
patients about 3 months [23], a recent randomized phase III study of HCC patients (n=1,114) 
after surgical resection or ablation demonstrated that Sorafenib treatment did not significantly 
improve patient overall and recurrence-free survivals [24]. Thus, the beneficial effects of 
Sorafenib for HCC patients are controversially discussed.  
Basic research and clinical trials are still ongoing to identify novel and druggable therapeutic 
targets, which may improve HCC patient's situation. For example, the PI3K/AKT pathway and 
mechanistic target of rapamycin (mTOR) are activated in HCC patients and mTOR inhibitors are 
currently used in clinical trials for HCC patients after surgical resection or TACE treatment [25]. 
This pathway is of special relevance since it has been shown that a number of oncogenic 
pathways and cellular mechanisms may activate the PI3K/AKT signaling axis [26]. Therefore, a 
deeper understanding of the underlying molecular mechanisms may help to identify HCC patients 
that may benefit from specific PI3K/AKT-directed inhibition approaches.  
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Figure 2: HCC development and current treatment options. The scheme illustrates the process of liver 
cancer development and progression. Risk factors that promote the progression from chronic liver diseases to 
HCC are summarized. Most relevant risk factors and pathogenenic mechanisms are listed. Therapeutic 
approaches for early/progressed HCC are mentioned next to the green arrow. Figure modified according to 
“Natural history of chronic liver disease” [2].  
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1.2 Epithelial cell polarity 
1.2.1 Cell polarity is important for epithelial cell functionality 
A high degree of cell polarity is a basic feature of many epithelial cells. The most important 
characteristic of epithelial cell polarity is the partitioning of plasma membrane into apical, lateral 
and basal domains. The apical domain refers to the membrane surface facing to cavities of 
organs. The lateral domain keeps close connection and cell-cell contact between adjacent cells, 
while the basal domain has direct contact with ECM or the basal lamina [27]. Cell polarity and 
membrane segregation are essential for epithelial cells to carry out their biological functions such 
as directional transport (absorption and secretion) of nutrients and salt between the extracellular 
environment and tissues. Intracellularly, it facilitates the molecular trafficking between 
organelles, e.g. from endoplasmic reticulum (ER) to the Golgi complex. In addition, cell polarity 
plays an essential role in keeping cell morphology, which is essential in different biological 
events, such as differentiation, migration and epithelial to mesenchymal transition (EMT) [28]. 
The establishment of cell polarity has been studied in a variety of cell types under different 
physiological and pathological conditions. Spatial orientation was first described during 
embryogenesis and tissue development, which is characterized in the following steps: a) initial 
appearance of cell-cell contact, b) assembly of cell junctions and c) establishment of epithelial 
cell morphology [29]. In these steps, cell junction-associated molecules are of special importance 
for the formation of cell polarity. For example, tight junctions (TJs), which mediate strong cell-
cell contact between adjacent cells, are important in the initiation and maintenance of epithelial 
cell polarity and define the boundary between apical and lateral domains. TJs include 
transmembrane proteins (e.g. occludin and claudin), junctional adhesion molecules (JAM, e.g. 
JAM-A, JAM-B) and peripheral membrane proteins (e.g. zonula occludens-1) attached to 
cytoskeleton [30]. In addition to TJs, adherens junctions (AJs) have also been found to be 
indispensable in the maintenance of cell polarity. The transmembrane protein E-cadherin is the 
core component of AJs, which allows a tight physical interaction of neighboring cells via the 
formation of homodimer and binding of extracellular domains. In addition, E-cadherin forms a 
complex with intracellular catenin proteins, which on one hand mediate the interaction with the 
actin cytoskeleton and on the other hand affect signal transduction [31].  
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Establishment and maintenance of cell polarity and junctional structures are a fundamental 
characteristic of epithelial cells to carry out their respective functions under various biological 
conditions. However, in addition to the core proteins directly involved in the assembly of TJ and 
AJ, other proteins and lipids, which are associated with cell-cell junctions, also participate in the 
process of epithelial polarization. A considerable number of factors has emerged to a complex 
network, which include epithelial polarity program (EPP) polarity protein complexes, Rho 
GTPases and polarity lipids [28]. 
 
1.2.2 Key players of EPP: Polarity complexes  
Polarity complexes refer to groups of proteins that are found in close proximity to certain polarity 
domains. These protein complexes are associated with the core proteins of cell junctions, and 
play a central role in EPP. So far, three polarity complexes have been described: the Crumbs 
complex, the Par complex and the Scrib complex. The Crumbs complex consists of 
transmembrane Crumbs (CRB), protein associated with Lin-7 1 (PALS1) and PALS1-associated 
tight junction protein (PATJ).  The Crumbs complex is located at apical cellular domains, which 
directly affect the assembly of TJ structures [32]. The Par complex comprises the proteins 
partitioning defective-3 (Par3, synonym: Baz), partitioning defective-6 (Par6) and atypical 
protein kinase C (aPKC).  It is located near subapical cell domains where it interacts with core 
proteins of both TJ and AJ [33]. The Scrib complex is composed of scribbled planar cell polarity 
protein (Scrib), discs large (Dlg) and lethal giant larvae (Lgl, LLGL1 in human). This complex 
defines the basolateral domain of epithelial cells and is critically involved in the formation of AJ, 
probably in an E-cadherin-dependent manner [33] (Figure 3).  
Although different polarity complexes are defined by their specific localization at the plasma 
membrane, they are not mechanistically separated from each other. Instead, polarity proteins 
from different complexes frequently communicate with each other in terms of an active protein 
exchange. These interactions result in either the recruitment of different proteins in the same 
complex or the competitive integration of individual proteins in different complexes. This 
mechanism of communication between polarity complexes is defined as “mutual exclusion” [33]. 
For example, the Par complex constituent aPKC is integrated in the apical Crumbs complex at 
early stages of Drosophila embryogenesis. In later developmental stages, it is recruited by Par3 to 
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the Par complex near the subapical domain [34]. In contrast, Par6, an adaptor protein for aPKC, 
binds and mediates the inactivation of Lgl, which is a major component of Scrib complex, via the 
phosphorylation by aPKC. Inactivated/Phosphorylated Lgl is then excluded from the subapical 
domain [35]; see Figure 3. Thus, through interactive communication with each other, cell polarity 
complexes represent highly dynamic modules that can adjust the cellular shape and functionality 
according to extracellular and endogenous requirements. 
 
 
Figure 3: Polarity complexes and spatial 
membrane organization of epithelial cells. 
The scheme shows the three main polarity 
complexes in an epithelial cell. The specific 
membranous domains are indicated by 
different colors. The apical domain, lateral 
domain and basal domain of this epithelial 
cell are shown in dark red, yellow and 
green, respectively. TJ and AJ are located at 
the lateral domain. Integrin connects the 
basal domain with the underlying 
extracellular matrix. The arrows indicate the 
phosphorylation of CRB (Crumbs complex) 
and Lgl (Scrib complex) by aPKC (Par 
complex), illustrating the dynamic 
interaction of proteins with polarity 
complexes.  
 
 
 
 
1.2.3 Crosstalk between Rho GTPases and polarity complexes 
In addition to the polarity complexes, Rho GTPases are also central regulators of the EPP system. 
Rho GTPases belong to small G proteins of the Ras family, which bind to GTP or GDP and 
catalyze the hydrolysis of GTP [36]. During the formation and maintenance of cell polarity, Rho 
GTPases modulate epithelial morphology through the re-organization of the cellular cytoskeleton. 
The Rho GTPases family consists of about 20 different GTPases, including RhoA, Rac1 and 
CDC42. Importantly, different GTPases carry out their functions at specific subcellular regions 
[37]. For example, RhoA interacts with actin-myosin filaments in the cytoplasm, which affects 
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membrane retraction during different biological process, e.g. cytokinesis [38]. CDC42 and Rac1 
are both found at the leading edge of migrating cells, where they regulate actin filament 
polarization and induce lamellipodia formation [39]. The specific subcellular localization of Rho 
GTPases suggests that they may have functional relevance in the regulation of polarity 
complexes. 
Indeed, Rho GTPases and cell polarity proteins are frequently interacting under different 
physiological and pathological conditions. For example, in the process of EMT, CDC42 binds to 
Par6 and facilitates the activity of aPKC-Par6 complex [39]. In addition, the aPKC-Par6 complex 
activates Rac1 via the RAC-specific guanine nucleotide exchange factor (GEF) T-cell lymphoma 
invasion and metastasis 1 (TIAM1) [40]. In addition, aPKC also activates p190A Rho GTPase 
activating protein (GAP), which switches off the activity of RhoA [39]. With the help of the Par 
complex, CDC42 induces the activity of Rac1 at lamellipodia, and inhibits the activity of RhoA 
in the cytosol. As a result, the Par complex promotes cell motility in the process of EMT via the 
modulation of different Rho GTPases [39]. Thus, cell polarity complexes communicate with Rho 
GTPases in the fine adjustment of cell cytoskeleton dynamics, which is essential in the 
modulation of cell morphology and motility. 
 
1.2.4 Disturbance of cell polarity in cancer development 
Loss of cell polarity is frequently found at early stages of epithelial tumor formation. For 
example, disruption of epithelial sheets, aberrant multilayering and loss of physiological lumen 
are typical features in early tumor development. However, disturbance of cell polarity is more 
than a consequence of tumor development [27]. This conclusion is supported by the fact that 
polarity proteins in different tumor types are frequently altered by genomic amplifications, 
deletions and mutations. For example, Dlg, Lgl and PATJ are downregulated, while Par6 is 
amplified and overexpressed in different cancer types [33]. Nevertheless, for some polarity 
proteins (e.g. Scrib, aPKC and Par3) both overexpression and downregulation have been 
described in several tumors suggesting that different mechanisms might be involved in the 
development of cancers [33, 41, 42].  
Cell division/proliferation can be affected by disturbed cell polarity. During asymmetric cell 
division, some important proteins and RNAs are segregated into daughter cells, which determine 
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the fate of daughter cells in differentiation [43]. This process of asymmetric localization is 
dynamically modulated by the polarity proteins, e.g. aPKC and Par-proteins via phosphorylation 
and mutual exclusion. Mutation and dysfunction of these polarity proteins lead to dysfunctional 
asymmetric cell division. As a result, cells continue with symmetric divisions without cell cycle 
termination, which may give rise to tumors [43]. In addition to the disturbed asymmetric division, 
pathways that directly regulate mitosis such as the Hippo pathway can be activated or inactivated 
by disturbed cell polarity in cancer development [33].  
Cell invasion/metastasis is also affected by disturbed cell polarity during tumor progression. Loss 
and reestablishment of cell polarity is necessary for tumor cells to leave the original localization 
and to achieve metastatic properties. In this context, EMT, which is highly relevant during 
embryogenesis, is of special importance for initial steps in tumor cell dissemination 
dissemination [44]. The process of EMT is directly connected with cell polarity, since the loss of 
the AJ molecule E-cadherin, as well as overexpression of N-cadherin and vimentin is regarded as 
important characteristics of EMT [19]. In addition to E-cadherin, Rho GTPases also play a 
central role in EMT via the interaction with cell polarity proteins. As described earlier, important 
positive regulator of EMT (CDC42 and RAC) are activated by polarity protein Par6 and aPKC 
(see chapter 1.2.3). Indeed, Par6 overexpression has been found to induce tumor metastasis in 
breast cancer via the activation of EMT-associated signaling pathway [33, 45].  
Therefore, genetic alterations as well as abnormal localization of polarity proteins are associated 
with tumor progression via cell dedifferentiation, cell proliferation, EMT and early metastasis 
[33].  
 
1.2.5 Disturbance of cell polarity affects oncogenic signaling pathways 
Recent studies have focused on the molecular mechanisms how dysregulation of the EPP system 
affects tumorigenesis. Cell polarity proteins integrate extracellular information into intracellular 
pathway responses and a dysregulation of cell polarity proteins is supposed to affect these tumor-
relevant downstream signaling pathways. Indeed, several oncogenic pathways have been 
identified to be modulated by EPP components. Here, mutations of single polarity proteins or 
disruptions of polarity complexes accounts for the activation of intracellular oncogenic pathways 
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[33]. Among these, the Hippo/yes-associated protein (YAP) and Wnt pathways are two 
examples, which affect tumor development and progression in different tissues. 
The Hippo/YAP pathway is essential for organ size control and HCC development [46]. First 
evidences already illustrated that the apical membrane protein FERM domain-containing protein 
6 (FRMD6) regulates the Hippo/YAP pathway. Specifically, FRMD6 forms a complex with two 
other apical membrane proteins, kidney and brain expressed protein (Kibra) and neurofibromin 2 
(NF2, synonyms: Merlin). The FRMD6/NF2/Kibra complex induces the phosphorylation of 
Hippo pathway component large tumor suppressor kinase 1 (Lats1), which results in the 
dephosphorylation and degradation of the transcriptional co-activator YAP in the cytoplasm. 
Thus, the apical complex FRMD6/NF2/Kibra acts as a tumor suppressor via the negative 
regulation of oncogenic YAP activity [47, 48]. In addition, other EPP components have also been 
identified as upstream modulators of the Hippo/YAP pathway. For example, Angiomotin 
(AMOT), which is usually localized in close proximity to apical Crumbs complex and which 
contains Proline-Proline-x–Tyrosine (PPxY) motifs, binds directly to the WW domain of YAP 
and its homolog WW domain containing transcription regulator 1 (WWTR1, synonyms: TAZ). 
The interaction between AMOT and YAP/TAZ fosters the localization of YAP/TAZ to TJs, 
which is associated with their inactivation [49]. Besides this, independent studies have shown the 
regulatory effect on YAP/TAZ by the basolateral Scrib complex, and the apical Crumbs 
complexes [50, 51]. 
 
Figure 4: Known EPP regulators of Hippo/YAP 
pathway. Scheme shows the apical polarity 
complex NF2/FERM6/Kibra that mediates the 
phosphorylation of macrophage stimulating 1/2 
(Mst1/2), which is a major component of Hippo 
pathway. Phosphorylation of Mst1/2 turns on the 
Hippo kinase cassette, including phosphorylation of 
Lats1/2 and YAP. Except for the NF2/FERM6/Kibra 
complex, AMOT directly binds to YAP, leading to 
the cytoplasmic retention of YAP near TJs. The 
interaction between AMOT and YAP may also 
induce phosphorylation of YAP by the Hippo 
pathway components. Phosphorylated YAP is 
degraded by ubiquitination or kept in the cytoplasm 
by 14-3-3 protein binding. In this case, YAP cannot 
bind to its transcriptional co-activator TEAD, 
leading to the repression of YAP-target genes.  
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Wnt pathway is another example for an EPP-relevant signaling pathway, which plays an essential 
role in defining cell fate determination (canonical pathway) and regulation of cell movement 
(non-canonical pathway) [52]. The canonical Wnt pathway depends on the AJ-associated protein 
β-catenin, which activity is inhibited after binding to a protein complex consisting of 
adenomatosis polyposis coli (APC), glycogen synthase kinase 3 (GSK3) and Axin [53]. Followed 
by Wnt ligand binding to the receptors Frizzled (Fz) and low density lipoprotein receptor-related 
protein 5/6 (LRP5/6), the APC/GSK3/Axin complex is recruited to the plasma membrane by 
LRP5/6, which induces the translocation of β-catenin into the nucleus [53]. Nuclear β-catenin 
activates transcriptional factors T cell-specific transcription factor (TCF) and target genes 
involved in cell fate determination and oncogenesis [53]. Interestingly, Wnt signaling also 
activates a non-canonical pathway independent on β-catenin, which regulates cell morphology 
and movement via Rho GTPases [52]. Wnt stimulation activates a protein complex consisting of 
Dishevelled (Dsh) and Dishevelled associated activator of morphogenesis 1 (Daam1), which 
further increase the activity of RhoA in the rearrangement of actin filaments [54].  
It is worth mentioning that except of the Hippo/YAP and Wnt pathways, other signaling 
pathways (e.g. TGF-β) are also regulated by different cell polarity components [44]. Thus, EPP 
components play an important role in the transduction of extracellular signal, and regulation of 
intracellular signaling pathways related to cell division, differentiation and migration; while 
disruption of polarity complexes may lead to dysregulation of these pathways, which promotes 
cancer development via cell proliferation, dedifferentiation and metastasis.   
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1.3 Hepatocellular polarity and HCC development 
1.3.1 Liver function depends on hepatocellular polarization 
The important functions are carried out by the major liver cell type, the hepatocyte [1]. The 
physiological function of the hepatocyte strictly depends on the establishment and maintenance 
of hepatocellular polarity, including the formation of the well-defined apical, lateral and basal 
domains comparable to other epithelial cell types such as small intestinal cells [6]. However, 
hepatocytes establish a specific polarity domain composition, which is important for carrying out 
their functions [6]. For example, adjacent hepatocytes orient their apical domains towards each 
other to form small lumens, which further branch in 3-dimensional canalicular structures for bile 
secretion (Figure 5) [3]. Similar to the apical site, hepatocytes form extensions and protrusions at 
the basal domain in close proximity to the Space of Disse and LSECs, which is a requirement for  
a highly efficient transportation between hepatocytes and blood vessels [5]. In this way, 
maintenance of hepatocellular polarity supports the liver function under physiological conditions, 
whereas the disturbance of cell polarity can lead to dysfunction of liver and disease. 
  
Figure 5: Hepatocellular polarity. Scheme shows cell-cell junctions, which facilitate the cell-cell contact 
between two adjacent hepatocytes. The red membrane indicates the apical lumen. Iron pumps and transporters, 
e.g. MRP2 are expressed at this domain of hepatocyte, which are important for bile secretion. The yellow 
membrane indicates the lateral domain of hepatocytes, where AJs and TJs are located. The green colored 
membrane represents the basal domain in direct contact with the Space of Disse. BC: bile canaliculus. 
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1.3.2 Disturbance of hepatocellular polarity in early HCC development  
Disturbance of cell polarity is considered to be an early event in epithelial tumor development 
[27]. In the liver, during liver fibrosis and cirrhosis, excessive matrix deposition reduces the cell 
contact with sinusoidal blood or neighboring hepatocytes, which eventually leads to regenerative 
nodules [6]. In HCC, the loss of hepatocellular polarity is detected in the early stage of 
hepatocarcinogenesis such as dysplastic nodules. The “plate-like” structures with clear porto-
central architecture are replaced by pseudoglandular structures in neoplastic livers [55]. 
Furthermore, discontinued canaliculi formation with the mislocalization of canalicular proteins 
(Na
+
-K
+ 
ATPase and alkaline phosphatase) are detectable in preneoplastic lesions [56]. 
Interestingly, the morphology of neoplastic hepatocytes have a high similarity with polypotent 
embryonic or hepatocytes after damage, which is also mirrored by the regression of cellular 
polarization during liver regeneration [6]. These observations suggest that the disturbance of 
hepatocellular polarity happens at early steps in tumorigenesis, which may play a specific role in 
the pathogenesis of liver cancer. 
The development HCC is associated with the dysregulation of cell polarity factors and relevant 
proteins such as liver kinase B1 (LKB1) and inositol polyphosphate phosphatase-like 1 
(INPPL1), for which a direct impact on hepatocarcinogenesis have been discussed [57]. The 
kinases LKB1 and its effector 5'-AMP-activated protein kinase (AMPK) play an important role in 
the maintenance of cell polarity via direct regulation on polarity protein Par1, and modulation on 
other polarity components (Scrib and Crumbs complexes) [58]. Mutations of LKB1 and AMPK 
disturb hepatocellular polarity and induce tumor formation in the liver in mouse model [57]. In 
addition to LKB1, the AJ protein E-cadherin also shows important function in HCC development. 
Loss of membranous E-cadherin is associated with an EMT phenotype and intrahepatic 
metastasis in HCC patients [16]. 
In summary, loss of hepatocellular polarity is an early event in liver tumor development. Several 
polarity proteins and polarity-associated pathway have been connected with hepatocarcinogenesis 
[57]. However, if a general loss of cell polarity or a disturbance of a certain polarity complex is 
important for liver tumorigenesis remains unknown. 
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2 OBJECTIVES 
Maintenance of cell polarity is considered to facilitate tumor-suppressor functions in epithelial 
cells. Disturbance of the spatial epithelial cell organization leads to a loss of function and has 
been discussed to be involved in the initiation and progression of cancers. For the liver, a high 
degree of hepatocellular polarization is important to fulfill its biological functions, including 
deteoxification and bile production. So far, it is not fully understood if and how the spatial 
disturbance of hepatocellular polarization can promote liver carcinogenesis. It is also unknown 
which specific molecular mechanisms are induced by the dysregulation of cell polarity 
constituents. For these reasons, the objectives of this study are:   
1. Identification of cell polarity-associated genes that are significantly dysregulated in human 
HCC samples in comparison to non-malignant liver tissues.  
2. Defining the expression/localization of selected cell polarity proteins in HCC cells and tissues. 
3. Establishment of an in vitro model for the functional und molecular characterization of the 
identified polarity proteins. 
4. Confirming the vivo relevance of the identified polarity gene in liver tumor formation using a 
hydrodynamic gene delivery approach.  
5. Identification of effector mechanisms induced by the dysregulation of the selected polarity 
proteins.   
6. Corroboration of findings in an independent HCC sample cohort.  
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3 MATERIALS 
 
3.1 Consumables 
Consumables and plastic ware used in this study are listed in Table 1.  
Table 1: Consumables 
Substance Company 
Cell culture plates TPP, Trasadingen, Switzerland 
Coverslips and slides Engelbrecht, Edermünde, Germany 
Parafilm Pechiney, Düsseldorf, Germany 
Matrigel Matrix-coated Transwells Corning, Wiesbaden, Germany 
PCR 96 well plate Applied Biosystems, Thermo Fisher Scientific, 
Langenselbold, Germany 
PCR reaction tubes Life science, Brand, Wertheim, Germany 
Nitrocellulose membrane 0.4 µm GE Healthcare, Freiburg, Germany 
Cell scrapper Corning 
Whatman paper GE Healthcare 
Sterile vacuum-filter 0.22µm Corning 
Mr. Frosty™ Freezing Container Thermo Fisher Scientific 
Eppendorf tubes Eppendorf, Hamburg, Germany 
Precellys tubes 
Bertin Technologies, Montigny-le-Bretonneux, 
France 
Cryovials Sigma-Aldrich, Taufkirchen, Germany 
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3.2 Equipment 
Table 2: Equipment 
Name Company 
12-Tube Magnet Qiagen, Hilden, Germany 
Agarose gel electrophoresis  Kreutz Reiskirchen, Germany 
AlphaImager™ Gel Imaging System Biozym Scientific, Hessisch Oldendorf, Germany 
Laminar Flow Hood Kojair Tech, Vilppula, Finland 
Centrifuges (MIKRO 200 R) M.S. Laboratories, Wiesloch, Germany 
CO2 atmosphere  Sigma-Aldrich 
FLUOstar Omega Microplate Reader BMG Labtech, Ortenberg, Germany 
Fume hood (Secuflow) Waldner, Wangen, Germany 
Immunofluorescence Microscope (CKX41) Olympus, Eislingen, Germany 
LI-COR Odyssey® Imaging System LiCor Biosciences, Bad Homburg, Germany 
Nanodrop Spectrometer (ND-1000) Thermo Fisher Scientific 
PH Meter (pH210) Hanna Instruments, Vöhringen, Germany 
PCR cycler (PTC-200) Bio-Rad Laboratories, München, Germany 
Rolling shaker (CAT RM5) Neolab, Heidelberg, Germany 
StepOne Plus Thermo Fisher Scientific 
Sonicator (S-4000) Qsonica, Newton, USA 
SDS-PAGE electrophoresis Bio-Rad Laboratories 
Thermomixer Eppendorf 
Western immunoblotting chambers Bio-Rad Laboratories 
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3.3 Reagents 
3.3.1 General reagents 
General reagents including chemicals, transfection reagents, polymerase chain reaction (PCR) 
reagents etc. are listed in Table 3. 
 
Table 3: Chemicals, transfection reagents and PCR reagents 
Substance Company 
2-Mercaptoethanol Roth, Karlsruhe, Germany 
Acetic acid Sigma-Aldrich 
Agarose Roth 
Ammonium persulfate (APS) Roth 
Avidin and biotin Kit  Vector Laboratories, Burlingame, USA 
ABsolute qPCR SYBR Green ROX Mix  Thermo Fisher Scientific 
Bovine Serum Albumin (BSA) Sigma-Aldrich 
Bradford reagent Sigma-Aldrich 
Cycloheximide (CHX) Sigma-Aldrich 
10x Cell Lysis Buffer Cell Signaling/New England Biolabs, Frankfurt, 
Germany 
Dimethyl sulfoxide (DMSO) Thermo Fisher Scientific 
Dynabeads Protein G Thermo Fisher Scientific 
dNTP-Mix Thermo Fisher Scientific 
Peroxidase Substrate (DAB) DAKO, Hamburg, Germany 
Ethanol Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EDTA) Serva, Heidelberg, Germany 
Fugene HD transfection reagent Thermo Fisher Scientific 
Formaldehyde (37%) Merck, Darmstadt, Germany 
Geneticin (G418) Thermo Fisher Scientific 
GeneRuler DNALadder Mix Thermo Fisher Scientific 
Glycine Sigma-Aldrich 
Hydrochloric acid (HCl) Merck 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) Roth 
Horseradish peroxidase (HRP) system  DAKO 
Igepal CA 6 Sigma-Aldrich 
Isopropanol Sigma-Aldrich 
Rat-tail tendon collagen I Roche, Mannheim, Germany 
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Lipofectamine® RNAiMAX Life Technologies, Darmstadt, Germany 
Magnesium chloride hexahydrate Roth 
Methanol Sigma-Aldrich 
Na-deoxycholate Roth 
Sodium chloride (NaCl) Roth 
Protease inhibitor Serva, Heidelberg, Germany 
Phosphotaseinhibitor PhosStop  Roche 
PageRuler Prestained Protein Ladder Thermo Fisher Scientific 
Paraformaldehyde (PFA) Merck 
Phosphate-buffered saline (PBS) GE Healthcare 
Phenylmethylsulfonyl fluoride (PMSF) Merck 
REAL Hematoxylin  DAKO 
Recombinant human SPARC R&D Systems, Wiesbaden, Germany 
Salmon sperm DNA Thermo Fisher Scientific 
Tetramethylethylenediamine  Roth 
Tris-hydroxymethyl-aminomethane (Tris) Roth 
Triton x-100 Merck 
Tween 20 Sigma-Aldrich 
Trypsin/EDTA PAA Laboratories, Cölbe, Germany 
Wortmannin Sigma-Aldrich 
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3.3.2  Solutions and buffers 
Table 4: Solutions and buffers 
Lysis Buffer (for Co-IP) RIPA Buffer 
Tris-HCl pH 7.4                     
Igepal CA 630 (NP40)           
Na-deoxycholate                   
NaCl                                      
EDTA                                     
PMSF                                     
50 mM 
1% 
0.25% 
150 mM 
1 mM 
1 mM 
NaCl                               
SDS                                      
Na-deoxycholate      
Igepal CA 630 (NP40)          
EDTA                       
Tris (pH8.0) 
  
 
150 mM 
0.1%  
0.5% 
1% 
5 mM   
50 mM 
IP-Wasch Buffer TE Buffer 
Tris (pH 8.5)  
LiCl                   
NP40                                    
Na-deoxycholate      
   
 
100 mM 
500 mM 
1%   
1% 
Tris (pH 8.0)  
EDTA                
 
70 mM 
1 mM 
Talianides Buffer 4X SDS-PAGE loading buffer 
Tris (pH 8.0) 
EDTA                   
SDS                   
 
70 mM 
1 mM 
1.5% 
TrisHCl (pH 6.8)                
DTT                                 
SDS                                   
Bromophenol blue            
Glycerol                            
 
200 mM 
400 mM 
8% 
0.4% 
40% 
Borate buffer TBS Buffer 
Boric acid                      
NaCl                               
Sodium tetraborate         
Adjust the pH to 8.4 
 
100 mM 
75 mM 
25 mM 
TrisHCl (pH 6.8)                 
NaCl                                  
Adjust the pH to 7.6 
50 mM 
150 mM 
Caspase Lysis Buffer Caspase Assay Buffer 
TrisHCl (pH 7.4)               
NaCl                               
Glycerin                           
Triton X-100                     
EDTA                                
20 mM 
137 mM 
10% 
1% 
2 mM 
HEPES (pH 7.5)                 
NaCl                                
EDTA                               
Glycerin                            
50 mM 
50 mM 
10 mM 
5% 
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3.3.3 Enzymes 
Restriction enzymes, DNA polymerase and transcriptase used for cloning and PCR reaction are 
shown in Table 5. 
Table 5: Enzymes for cloning 
Name Company 
DpnI restriction enzyme New England Biolabs 
EcoRI restriction enzyme Thermo Fisher Scientific 
Gateway® BP Clonase® II Enzyme mix Thermo Fisher Scientific 
Gateway® LR Clonase® II Enzyme mix  Thermo Fisher Scientific 
Phusion® High-Fidelity DNA Polymerase New England Biolabs 
Q5® High-Fidelity DNA Polymerase New England Biolabs 
REDTaq® ReadyMix™ PCR Reaction Mix Sigma-Aldrich 
RevertAid H Minus Reverse Transcriptase Thermo Fisher Scientific 
T4 Polynucleotide (PNK) Kinase New England Biolabs 
T4 DNA Ligase New England Biolabs 
Calf intestinal alkaline phosphatase (CIAP) Thermo Fisher Scientific 
 
3.4 Assays and Kits 
Table 6: Assays and Kits 
Name Company 
NucleoSpin® Gel and PCR Clean-up kit Macherey-Nagel, Düren, Germany 
Plasmid Miniprep kit Qiagen, Hilden, Germany 
Plasmid Midprep kit Promega, Mannheim, Germany 
EndoFree Plasmid Maxiprep kit Qiagen 
NucleoSpin® RNA extraction kit Macherey-Nagel 
NE-PER Nuclear and Cytoplasmic Extraction kit Thermo Fisher Scientific 
Mem-PER Plus Membrane Protein Extraction Kit Thermo Fisher Scientific 
NucleoSpin® Gel and PCR Clean-up kit  Macherey-Nagel, Düren, Germany 
SPARC Quantikine ELISA kit R&D Systems, Wiesbaden, Germany 
CellTiter-Blue® Assay  Promega 
CellTox™ Green Cytotoxicity Assay Promega 
AP based DCS Detection Line system  DCS, Hamburg, Germany 
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3.5 Antibodies 
Antibodies and concentrations used for protein biochemistry analyses are listed in Table 7. 
Table 7: Antibodies 
Antigen (clone) Company Concentrat
ion 
Application 
ATF2 (20F1) Cell signaling 0.5 µg/ml WB 
ATF2 (N-96) Santa Cruz Biotechnology 3 µg ChIP 
Phospho-ATF2 Thr71 Cell signaling 0.5 µg/ml WB and IHC 
JunB (C37F9) Cell signaling 3 µg ChIP 
Phospho-JunB Thr102/Thr104 (D3C6) Cell signaling 0.5 µg/ml WB 
c-Jun (60A8) Cell signaling 0.5 µg/ml WB 
Phospho-c-Jun Ser73 Cell signaling 0.5 µg/ml WB 
PTEN (138G6) Cell signaling 1 µg/ml WB 
ß-Tubulin BD Pharmingen 0.5 µg/ml WB 
Scribble (K-21) Santa Cruz Biotechnology 0.67 µg/ml WB and IF 
Scribble Sigma 5 µg/ml IHC 
Fascin R&D 1 µg/ml WB 
PHLPP1 Bethyl 0.5 µg/ml WB 
E-cadherin Epitomics 5 µg/ml IF 
N-cadherin QED Bioscience 5 µg/ml IF 
AKT Cell signaling 1 µg/ml WB 
Phospho-Akt Ser473 Cell signaling 1 µg/ml WB 
S6 Ribosomal protein (5G10) Cell signaling 1 µg/ml WB 
Phospho-S6 Ribosomal protein Ser235/236 Cell signaling 1 µg/ml WB 
Na+-K+-ATPase Cell signaling 1 µg/ml WB 
P38 Cell signaling 1 µg/ml WB 
 Phospho-P38 Cell signaling 1 µg/ml WB 
SP1 Cell signaling 3 µg ChIP 
YAP Cell signaling 1 µg/ml WB 
Phospho-YAP (Ser127) Cell signaling 1 µg/ml WB 
GFP Tag Proteintech 2 µg IP 
MCAM (ME-9F1) Biolegend 5 µg/ml IHC 
MRP2 (R260) Cell signaling 10 µg/ml Sandwich 
culture IF 
Cy™3 AffiniPure Donkey Anti-Rabbit Jackson ImmunoResearch 3 µg/ml IF 
Alexa Fluor® 488 AffiniPure Donkey Anti-Goat Jackson ImmunoResearch 7.5 µg/ml IF 
ChIP: Chromatin Immunoprecipitation, IHC: Immunohistochemistry, IP: Immunoprecipitation,  
IF: Immunofluorescence, WB: Western Immunoblotting. 
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3.6 Oligonucleotides 
Primers for semi-quantitative polymerase chain reaction (qPCR) analysis were designed to span 
intronic regions of the respective genes. Primers were synthesized by Thermo Fisher Scientific 
and Apara-bioscience (Denzlingen, Germany). 
3.6.1 Primers for qPCR  
Table 8: qPCR primers 
Gene Accession Number Forward primer (5´-3´) Reverse primer (5´-3´) 
SCRIB NM_015356.4 AGGAAGACGCCGAAGAGGACTA AGTGCGTCCTCTGCGAAATG 
PTEN NM_000314.6 AGTGGCGGAACTTGCAATC GGTCCTGAATTGGAGGAA 
PHLPP1 NM_194449.3 AATGCCCTGCGATCAGTC CTTCATGTTCTCCAACTCAG 
SPARC NM_003118.3 GAAACTGTGGCAGAGGTGA GGTTTCCTCTGCACCATCAT 
FSCN1 NM_003088.3 CATCAAAGACTCCACAGGCAA GAAGAAGTCCACAGGAGTGT 
CEACAM1 NM_001712.4 GACCCAGTCACCTTGAATGT ACGGTAATAGGTGTCTGAAG 
S100A10 NM_002966.2 CCTGAGAGTACTCATGGAA GGTCCAGGTCCTTCATTAT 
TIMP1 NM_003254.2 CAATTCCGACCTCGTCATCA ACGCTGGTATAAGGTGGTCT 
TIMP2 NM_003255.4 TATCTCATTGCAGGAAAGGC GAAGTCACAGAGGGTGATGT 
JunB NM_002229.2 CTACCACGACGACTCATACA GCTCGGTTTCAGGAGTTTGT 
ATF2 NM_001880.3 GAGGAGCCTTCTGTTGTAGA GTGCAGTTTGTGCCAATGGT 
CDH2 NM_001792.4 TGGCAGCTGGACTTGATCGAG GACATCTGTCACTGTGATGACGG 
MCAM NM_006500.2 TGTGAGCTCAACTACCGGCT CTCCACTTCCAGCCACACT 
B2M NM_004048.2 CACGTCATCCAGCAGAGAAT TGCTGCTTACATGTCTCGAT 
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3.6.2 Primers for molecular cloning 
Table 9: Cloning primers 
Application Name Sequence (5‘-3‘) 
Amplification of hScrib 
for Gateway Donor 
vector 
Scrib forward 
GGGGACAAGTTTGTACAAAAAAGCAGGCTCCACCATGCTC
AAGTGCATCCCGCTG 
Scrib reverse 
GGGGACCACTTTGTACAAGAAAGCTGGGTTCTAGGAGGGC
ACAGGGCCCAG 
hScribP305L mutagenesis 
Scrib (mut-P305L) forward CTGCTGATGGCCCTGCTCCGCTCCCTGGGAAAGC 
Scrib (mut-P305L) reverse GCTTTCCCAGGGAGCGGAGCAGGGCCATCAGCAG 
Amplification of hScrib 
for cloning into the pT3-
EF1α vector 
Scrib pT3 for tacACGCGTATGCTCAAGTGCATCCCGCTGT 
Scrib EcoRI pT3 rev attGAATTCCTAGGAGGGCACAGGGCCCAGG 
Bold and underlined letters indicate the mutation point. 
 
3.6.3 Primers for Chromatin Immunoprecipitation (ChIP) analysis  
Primers for ChIP analysis were designed to span an amplicon between 80-120 bp containing the 
transcription factor binding site. Control primers were designed to amplify downstream regions 
with no binding sites.  
 
Table 10: ChIP primers 
Name Accession number Sequence (5´-3´) 
SPARC binding site 1 forward ENSG00000113140 GTGGTACAAGTGGAGTTTGAGTG 
SPARC binding site 1 reverse ENSG00000113140 CAGGACTTACCACTGTACAGAC 
SPARC binding site 2 forward ENSG00000113140 GCCTGGAGAAGGAATCAACT 
SPARC binding site 2 reverse ENSG00000113140 AAAGGTTACCGTGGCAACTC 
SPARC control forward ENSG00000113140 GTCTAGCTCATGGCAGCAAATC 
SPARC control reverse ENSG00000113140 AATGTGGAGCCCAGAGGCTAT 
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3.6.4 Small interfering RNA (siRNA) 
SiRNAs were purchased from Qiagen or Eurofins Scientific (Ebersberg, Germany).  For PTEN, a 
27-mer Dicer substrate siRNA method was used for the design of siRNAs [59]. For the other 
genes, a traditional 19-21mer siRNA method with dTdT overhangs was applied. Sequences of 
sense and antisense strands as well as concentrations for each siRNA are shown in the following 
table.  
 
Table 11: siRNA 
Gene name 
Accession 
number 
Sense (5´- 3´) Antisense (5´- 3´) 
Used 
concentration 
PTEN#1 NM_000314.6 
UAGCAGAAACAAAAGGAGA
UAUCdAdA 
GAUAUCUCCUUUUGUUUC
UGCUAAC 
20 nM 
PTEN#2 NM_000314.6 
GAAUCAUCUGGAUUAUAG
ACCAGdTdG 
CUGGUCUAUAAUCCAGAU
GAUUCUU 
20 nM 
PHLPP1#1 NM_194449.3 
GAAGAGCUGAAGAGGAUU
AdTdT 
UAAUCCUCUUCAGCUCUUC
dTdT 
20 nM 
PHLPP1#2 NM_194449.3 
AUAACAGCCUCACAGACAA
dTdT 
UUGUCUGUGAGGCUGUUA
UdTdT 
20 nM 
SCRIB#1 NM_015356.4 
GGCAGCGGCTCATCCGCAA
dTdT 
UUGCGGAUGAGCCGCUGC
CdTdT 
30 nM 
SCRIB#2 NM_015356.4 
CAGGAUGAAGUCAUUGGA
ACAdTdT 
UGUUCCAAUGACUUCAUCC
UGdTdT 
30 nM 
JUN NM_002228.3 
AAGAACGUGACAGAUGAG
CAGdTdT 
CUGCUCAUCUGUCACGUUC
UUdTdT 
30 nM 
ATF2 NM_001880.3 
CGCGGGUGACCGAAAGGA
UCAdTdT  
UGAUCCUUUCGGUCACCCG
CGdTdT 
30 nM 
JUNB NM_002229.2 
ACAGACUCGAUUCAUAUU
GAAdTdT 
UUCAAUAUGAAUCGAGUC
UGUdTdT 
30 nM 
SPARC NM_003118.3 
ACCCAAGACAUGACAUUCU
UAdTdT 
UAAGAAUGUCAUGUCUUG
GGUdTdT 
30 M 
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3.7 Cell lines 
3.7.1 Liver cancer cell lines 
Liver cancer cell lines were purchased from the American Type Culture Collection (ATCC, 
Manassas, Virginia, USA). Cell lines were routinely confirmed by short tandem repeats profiling. 
Liver cancer cell lines and cell culture conditions are listed in Table 12-13. Liver cancer cell lines 
were seeded in hepatocyte sandwich culture, which allowed the establishment of apical lumens of 
canaliculi, and was used to analyze the extent of hepatic polarization [6]. MRP2 was used to 
visualize the canaliculi structure in hepatocyte sandwich culture. Liver cancer cell lines with 
different capacities of polarization were compared in Table 12. 
Table 12: Liver cancer cell lines 
Name Tissue Cell type Disease Cell polarity 
HepG2 liver epithelial   Hepatoblastoma High 
HuH1 liver epithelial   HCC High 
HuH6 liver epithelial   Hepatoblastoma High 
HuH7 liver epithelial   HCC Low 
HLE liver epithelial   HCC Low 
HLF liver epithelial   HCC Low 
Hep3B liver epithelial   HCC Low 
SNU182 Liver Epithelial   HCC Low 
 
3.7.2 Cell lines culture media 
Table 13: Cell culture media and supplements 
Name Media Supplement 
HepG2 RPMI-1640 (GE Healthcare) 
10% FCS (GE Healthcare)+ 1% 
Penicillin/Streptomycin (P/S) (GE Healthcare) 
HuH1 DMEM (GE Healthcare) 10% FCS+ 1% P/S 
HuH6 DMEM 10% FCS+ 1% P/S 
HuH7 DMEM 10% FCS+ 1% P/S 
HLE DMEM 10% FCS+ 1% P/S 
HLF DMEM 10% FCS+ 1% P/S 
Hep3B MEM 10% FCS+ 1% P/S 
SNU182 RPMI-1640 10% FCS+ 1% P/S 
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3.8 Bacterial strands  
Table 14: Bacterial strands for cloning 
Name Application Company Description/Genotype 
NEB® 5-alpha 
Competent E. coli  
Gateway vectors New England Biolabs Mutations in recA1 and 
endonuclease I (endA1) 
NEB
®
 Stable 
Competent E. coli 
pT3-EF1α vector New England Biolabs Eliminated activity of endA1 
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3.9 Plasmid maps 
 
 
Figure 6: Plasmid maps of Scrib vectors. (A) Plasmid maps for pEGFP-Scrib
WT
 and pEGFP-Scrib
P305L
. 
Inserts are located after a cytomegalovirus (CMV) promoter. This vector produces a fusion protein of Scrib
WT 
or Scrib
P305L
 with an N-terminal EGFP-tag. The attR recombination sites of Gateway system and Scrib 
mutation point (P305L) are indicated. (B) Plasmid maps for pT3-EF1α-Scrib
WT
 and pT3-EF1α-Scrib
P305L
 
vectors. Inserts are located after a human elongation factor-1 alpha (EF1α) promoter, which allows long-term 
expression of genes in mouse hepatocytes. Inverted Repeats (IR) defines, which is recognition sites for the 
transponase, are indicated. Internal ribosome entry site (IRES) sequence allows independent expression of 
Scrib
WT 
or Scrib
P305L
 and green fluorescent protein (GFP). 
METHODS 
 
30 
 
 
4 METHODS 
 
4.1 Cell culture 
4.1.1 Cultivation of immortalized liver cancer cell lines  
Human liver cancer cell lines were cultured in DMEM or RPMI supplemented with 10% FCS 
and 1% P/S at 37°C in a 5% CO2 atmosphere. Cell lines were authenticated by STR-analysis 
(DSMZ, Braunschweig, Germany) and were regularly checked for mycoplasma contamination. 
Cell lines and cell culture conditions are described in Chapter 3.7.1-2. All liver cancer cell lines 
were split every 3 days. In brief, cells on 10 cm dish were washed with 4 ml PBS, and incubated 
with 1 ml Trypsin/EDTA at 37°C for 5 minutes. After detaching, cell suspensions were seeded on 
10 cm dishes with pre-warmed cell culture media. For counting cells, 8 μl of cell suspension was 
added to the hemocytometer. Cells were counted in the four corners with gridded square under 
10x objective using an inverted microscope. The estimated cell number per ml equals to the 
average cell number multiplied by 10
4
. Subculture of cell lines and cell numbers used in different 
cell culture scales are listed in Table 15.  
 
Table 15: Subculture and cell seeding of liver cancer cell lines 
Cell line Subcultivation ratio Cell number (6-well) Cell number (6 cm) Cell number (10 cm) 
HepG2 1:4 3.0x10
5 
6.6x10
5
 1.8x10
6
 
HuH1 1:6 3.0x105 6.6x105 1.8x106 
HuH6 1:3 4.0x105 8.8x105 2.4x106 
HuH7 1:8 1.0x10
5
 2.2x10
5
 6.0x10
5
 
HLE 1:8 1.0x105 2.2x105 6.0x105 
HLF 1:10 1.0x10
5
  2.2x10
5
 6.0x10
5
 
Hep3B 1:3 3.0x105 6.6x105 1.8x106 
SNU182 1:6 2.0x105 4.4x105 1.2x106 
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4.1.2 Cryconservation of liver cancer cell lines 
Cells were cultured on 10 cm dishes until 70-80% confluence before cryconservation. One 
milliliter trypsin was added to each dish at 37°C for 5 minutes. After detaching, cells were 
resuspended in 8 ml cell culture media and centrifuged at 1000x rounds per minute (RPM) for 5 
minutes. After removing the supernatant, the remaining cell pellet was resuspended in 800 μl cell 
culture media supplemented with 20% FCS and transferred to 2 ml cryovials. An equal volume 
(800 μl) of cell culture media supplemented with 20% FCS and 20% DMSO (final concentration 
10%) was added to each cryovial. Vials were transferred into a freezing container at -80°C 
overnight, and stored in liquid nitrogen for long-time use.  
 
4.1.3 Preparation of HCC cell sandwich culture  
For the preparation of highly polarized 3D sandwich cultures, a collagen solution was prepared 
by dissolving rat-tail collagen I lyphilisate in sterile-filtered 0.2% (v/v) acetic acid overnight. 
Before use, the collagen solution was supplemented with concentrated DMEM medium (10x) and 
neutralized to pH 7.4 by adding NaOH (2 M) on ice. The collagen solution was completely 
dispensed on cell culture plates, which were incubated at 37°C for 1 hour to allow gelation. HCC 
cells (HepG2 or HuH6) were seeded on the collagen layer for at least 4 hours. After attaching, 
cells were washed once with ice-cold PBS. Additional collagen solution was dispensed on the 
upper layer of adherent cells. After 1 hour of gelation, the respective cell culture medium was 
added to the sandwich culture. HCC cell lines were cultured in collagen sandwich culture for 10 
days before further analyses. Cell culture media were changed every 3 days. Volumes of 
neutralized collagen solutions, cell culture media and numbers of cells used in different cell 
culture scales are listed in Table 16. 
 
Table 16: Sandwich culture preparation and cell plating 
Cell culture scale 
Neutralized collagen solution 
(for each layer) 
Number of HCC cell Media volume 
12 well plate 120 µl 5.6-7.2x10
4
 1.5 ml 
6 well plate 250 µl 1.4-1.8x10
5
 2 ml 
6 cm plate 500 µl 3.0-4.0x10
5
 6 ml 
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4.1.4 Generation of cell lines stably expressing ScribWT and ScribP305L 
For the generation of HCC cell lines stably expressing Scrib
WT
 or Scrib
P305L
, Fugene HD 
transfection reagent was used for the delivery of expression vectors. HepG2 cells were seeded on 
10 cm plates with 80% of confluence overnight. Transfection mixture consisting of pEGFP-
Scrib
WT
 or pEGFP-Scrib
P305L
 plasmids (9 µg), Fugene HD transfection reagent (42 µl) and Opti-
MEM was prepared with a total volume of 420 µl. After incubation at room temperature for 15 
minutes, the transfection mixture was distributed thoroughly to the HCC cells in 8 ml of 
transfection media (with 10% FCS, without antibiotics). G418 (1 mg/ml) selection was carried 
out 72 hours after transfection to allow the expansion of cells with stable integration of the 
vector. Single colonies started to appear 2 weeks of G418 selection. Colonies were carefully 
transferred to 96-well plates. For single colony expansion, a lower concentration of G418 (400 
ng/ml) was applied to the cell culture media. Cells were step-wise transferred to 24 -well plate, 6 
-well plate, and 6 cm plates. The transgene expression was confirmed by both western 
immunoblotting and real-time PCR (see 4.5.2 and 4.4.3). For further functional and gene 
expression analysis, the stable clones were cultured with full RPMI media without G418. 
Overexpression of exogenous Scrib was routinely checked by western immunoblotting every 
month.  
4.1.5 Small-interfering (siRNA)-mediated gene inhibition 
A reverse transfection protocol using Lipofectamine
®
 RNAiMAX was used for the transfection 
of siRNAs-mediated gene inhibition.  Treatment was carried out on 6-well plates. The siRNA 
solution (Table 17 solution A) and the Lipofectamine
®
 RNAiMAX solutions (Table 17 solution 
B) were prepared separately. SiRNA concentrations and target sequences of siRNAs are listed in 
Table 11. After incubation of solution A and B at room temperature for 10 minutes, solution B 
was added to solution A and incubated at room temperature for another 15 minutes. During this 
time, 3.5x10
5 
- 4x10
5
 cells were detached by trypsin and resuspended in 2.5 ml transfection media 
(with 10% FCS, without antibiotics). SiRNA transfection mixture (500 µl) and cell suspension 
(2.5 ml) were mixed well and transferred into a 6-well plate. Total RNA and proteins were 
extracted 48 to 72 hours after siRNA treatment. Cells without treatment as well as cells 
transfected with nonsense siRNA served as controls.  
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Table 17: Preparation of siRNA transfection solutions 
Solution Component Amount Final concentration 
A 
Opti-MEM 250 µl - 
SiRNA (20 µM) 3.0-4.5 µl 20-30 nM 
B 
Opti-MEM 250 µl - 
Lipofectamine
®
 RNAiMAX 7.5 µl 0.25% (v/v) 
 
 
4.1.6 Wortmannin treatment 
For the inhibition of PI3K activity, cells were treated with Wortmannin, which was dissolved in 
DMSO at 100 mM and stored light-protected at -20°C. One day before treatment, cells were 
seeded with a cell density of 7.5x10
3
/well in a 96-well plate or 3x10
5
/well in a 6-well plate. 
Wortmannin was pre-diluted in PBS to a concentration of 1 mM. Different working 
concentrations of Wortmannin (0.05, 0.1, 0.25, and 0.5 μM) were applied to the cells for 6.5 to 24 
hours. Cells treated with an equal amount of DMSO served as a control. 
 
4.1.7 Recombinant SPARC treatment 
Recombinant Human SPARC was reconstituted in PBS (final concentration: 100 μg/ml) and 
stored at -20°C. For the treatment, cells were seeded with a cell density of 6x10
4
 cells/well in 
FCS-free medium in 24-well plate of a Matrix-coated transwell chamber. In the lower chamber, a 
higher concentration of SPARC (200 ng/ml) was used to stimulate directional cell invasion. In 
the upper chamber, lower concentration of SPARC (20 ng/ml) was supplemented.  
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4.2 Functional assays 
4.2.1 Cell viability assay 
Cell viability was determined using the CellTiter-Blue reagent. Cells were seeded with a cell 
density of 7.5x10
3
/well in a 96-well plate. The CellTiter-Blue reagent was added to cultured cells 
according to the manufacturer's instructions. After 1 hour of incubation at 37°C, fluorescence was 
detected by a Fluostar Omega microplate reader at an excitation wavelength of 544 nm and an 
emission wavelength of 590 nm. Cell viability was detected 48 and 72 hours after respective 
treatments. 
4.2.2 Cell cytotoxicity and apoptosis assays 
CellTox Green reagent was employed for the measurement of cell cytotoxicity. Cells were seeded 
with a cell density of 7.5x10
3
/well in a 96-well plate overnight. Cell cytotoxicity was measured 
48 and 72 hours after seeding. For the measurement, cells were incubated with CellTox Green 
reagent at room temperature for 15 minutes according to the manufacturer's instructions. The 
fluorescence was subsequently measured at an excitation wavelength of 485 nm and an emission 
wavelength of 520 nm.  
Caspase-3 activity assay was used for the measurement of cell apoptosis. Proteins were extracted 
from cultured cells using the Protein Lysis buffer. Caspase-3 substrate Ac-DEVD-AFC (7-
Amino-4-trifluoromethylcoumarin, 100 µM in HEPES-Buffer) was prepared freshly according to 
the manufacturer's instructions. Protein lysate (50 µg) was incubated with the Caspase-3 substrate 
(50 µl) at 37°C for 4 hours. Caspase activity was detected at an excitation wavelength of 400 nm 
and an emission wavelength of 505 nm. Cells treated with cell culture medium served as negative 
controls, while cells treated with Doxorubicin (1 µM) were used as positive controls.  
4.2.3 Cell invasion assay 
Cell invasion experiments were performed using a matrigel invasion chamber with an 8 µm pore 
polycarbonate membrane. Cells were seeded on top of the matrigel with a cell density of 
6x10
4
/well in starvation medium. On the lower side of the invasion chamber, cell culture medium 
was supplemented with 10% FCS for a cell attractant. Cells remaining on the upper matrigel were 
removed by cotton tips after 48 to 96 hours, while transmigrating cells were fixed with 
paraformaldehyde (PFA, 4%, w/v) for 10 minutes. A crystal violet/methanol (5%, w/v) solution 
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was used for cell body staining on the polycarbonate membrane. After incubation with the crystal 
violet solution for 1 hour, the polycarbonate membrane was washed 3x with PBS, and 1x with 
distilled water. Seven different areas from each membrane were digitally documented and the 
numbers of transmigrating cells were visually counted (40-fold magnification).  
 
4.3 Molecular cloning 
4.3.1 Scrib cloning for the generation of stable cell lines 
Empty Gateway plasmids pDONR201 and pDEST-EGFP were kindly provided by Dr. Stefan 
Pusch (DKFZ, Heidelberg, Germany). Human pDEST-EGFP-Scrib
WT 
and pDEST-EGFP-
Scrib
P305L
 vectors for the generation of stable cell lines were constructed using the Gateway
®
 
system. Human Scrib complementary DNA (cDNA) was amplified from a human Scrib plasmid 
(pLK45) purchased from Addgene (Cambridge, Massachusetts, USA). For this, a proofreading 
Phusion
®
 High-Fidelity DNA Polymerase was employed for the amplification of Scrib cDNA. 
The reaction and program are shown in Table 18-19. 
 
Table 18: Amplification reaction of Scrib for pDONR201 
Component Amount Final concentration 
DNA template (pLK45-Scrib) 20 ng 0.4 ng/µl 
dNTP (10 mM) 1 µl 200 µM 
Scrib forward (10 µM) 2.5 µl 0.5 µM 
Scrib reverse (10 µM) 2.5 µl 0.5 µM 
5x Phusion
®
 GC buffer 10 µl 1 x 
DMSO 1.5 µl 3 % 
Phusion
®
 High-Fidelity DNA Polymerase 0.5 µl 0.02 units/µl 
Nuclease free water add to 50 µl - 
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Table 19: Amplification program of Scrib for pDONR201 
PCR cycle Step Temperature Time 
1 Initial denaturation 98 °C 30 seconds 
30x 
Denaturation 98 °C 30 seconds 
Combined annealing and extension  72 °C 3 minutes and 20 seconds 
1 Final extension 72 °C 10 minutes 
 
PCR product was separated on a 0.5% agarose gel, and extracted using the PCR Clean-up kit. 
The integration of Scrib cDNA in the Gateway
®
 pDONR 201 vector was performed using the 
Gateway
®
 BP Clonase II Enzyme Mix according to the manufacturers' instructions. In brief, 4 µl 
(30 fmol) of PCR product was incubated with pDONR vector (150 ng), Gateway
®
 BP Clonase
®
 
II Enzyme mix (2 µl), and filled up with TE buffer (pH 8.0) to 10 µl. The BP reaction was done 
at room temperature, overnight. In order to transfer the Scrib cDNA with Gateway
®
 expression 
vectors in other vectors, a LR reaction was performed using the Gateway
®
 LR Clonase II Enzyme 
Mix according to the manufacturers' protocol. In brief, 5 µl pDONR-Scrib (75 ng) Gateway
®
 
destination vector pDEST-EGFP (75 ng), Gateway
®
 LR Clonase
®
 II Enzyme mix (1 µl) and TE 
buffer (pH 8.0) were incubated together. LR reaction was carried out at room temperature for 4 
hours. All used constructs were confirmed by sequencing (Seqlab-Sequence Laboratories, 
Göttingen, Germany). 
4.3.2 Site-directed ScribP305L mutagenesis 
Site-directed mutagenesis was performed to include the P305L mutation in the wildtype form of 
Scrib [60]. For the generation of pDONR-Scrib
P305L
, forward and reverse strands were 
synthesized by PCR using complementary primers containing the desired mutation (Table 9). The 
reaction and program for new strand synthesis are shown in Tables 20-21. After that, methylated 
templates were digested using 1 unit of DpnI enzyme for 3 hours. The newly synthesized DNA 
carrying the P305L mutation was transformed into bacteria. The pDONR-Scrib
P305L
 vector was 
confirmed by sequencing. Subsequently, both pDONR-Scrib
WT
 and pDONR-Scrib
P305L
 were used 
to transfer Scrib
WT
 and Scrib
P305L
 in the pDEST-EGFP expression vector by using Gateway
®
 LR 
Clonase
®
 II Enzyme mix (Table 5). 
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Table 20: Reaction for ScribP305L mutagenesis 
Component Amount Final concentration 
DNA template (pDONR-Scrib) 100 ng 2 ng/µl 
dNTP (10 mM) 1 µl 200 µM 
Scrib (mut-P305L) forward (10 µM) 1 µl 0.2 µM 
Scrib (mut-P305L) reverse (10 µM) 1 µl 0.2 µM 
5x Phusion
®
 GC buffer 10 µl 1 x 
DMSO 1.5 µl 3 % 
Phusion® High-Fidelity DNA Polymerase 0.5 µl 0.02 units/µl 
Nuclease free water add to 50 µl - 
 
Table 21: Program for ScribP305L mutagenesis 
Cycle Step Temperature Time 
1 Initial denaturation 98 °C 60 seconds 
18 x 
Denaturation 98 °C 30 seconds 
Combined annealing and extension  72 °C 4 minutes and 40 seconds 
1 Final extension 72 °C 10 minutes 
 
 
4.3.3 Subcloning of ScribWT and ScribP305L for hydrodynamic tail-vein injection 
To generate the vectors for hydrodynamic tail-vein (HDTV) injection, human Scrib
WT
 and 
Scrib
P305L
 cDNAs were amplified by using Scrib pT3 for and Scrib EcoRI pT3 rev primers (Table 
9). Blunt-end cloning was employed for the transfer of the insert into the pT3-EF1α vector. PCR 
reaction and program for the implication of Scrib cDNA were indicated in the following tables 
(Table 22-23). Fifty microliters of PCR products were loaded on a 0.5% Agarose gel for 
separation. The specific product with 4.8 kb was cut out under UV light and purified using the 
PCR Clean-up kit. To phosphorylate the insert, 17 µl of purified PCR product was incubation 
with 1 µl T4 Polynucleotide Kinase (PNK) and 2 µl T4 ligation buffer at 37°C for 1 hour. T4 
PNK Kinase was inactivated at 65°C for 20 minutes. For the preparation of the backbone, the 
empty pT3-EF1α vector (2 µg) was digested with the restriction enzyme EcoRI (1 unit) at 37°C 
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for 3 hours. In order to generate blunt ends, Phusion
®
 polymerase (1 unit) and dNTPs (0.5 µl, 
final concentration: 250 µM) were incubated with the digested plasmid (2 µg) at 37°C for 1 hour. 
The blunt-end vector (17 µl) was dephosphorylated by CIAP (2 µl, 40 units) for 1 hour. The 
resulting pT3-EF1α vector was purified by PCR clean up kit. To ligate the ScribWT/ScribP305L 
cDNAs with the pT3-EF1α vector, the phosphorylated insert (250 ng) was added to the 
dephosphorylated vector (100 ng) with a molar ratio of 3:1 (insert:vector). T4 ligase (1 µl, 5 
units) and T4 Buffer (supplemented with ATP, 1 µl) were added to the DNA mixture and 
incubated at 16°C overnight. 
  
Table 22: Amplification reaction of Scrib for pT3-EF1α vector 
Component Amount Final concentration 
DNA template (pDONR-ScribWT/pDONR-ScribP305L) 20 ng 0.4 ng/µl 
dNTP (10 mM) 1 µl 200 µM 
Scrib pT3 for (10 µM) 2.5 µl 0.5 µM 
Scrib EcoRI pT3 rev (10 µM) 2.5 µl 0.5 µM 
5x Q5 buffer 10 µl 1 x 
5x High GC Enhancer 10 µl 1 x 
DMSO 1.5 µl 3 % 
Q5® High-Fidelity DNA Polymerase 1 µl 0.04 units/µl 
Nuclease free water add to 50 µl - 
 
Table 23: Amplification program of Scrib for pT3-EF1α vector 
PCR Cycle Step Temperature Time 
1 Initial denaturation 98 °C 30 seconds 
38x 
Denaturation 98 °C 5 seconds 
Combined annealing and extension  72 °C 3 minutes and 30 seconds 
1 Final extension 72 °C 2 minutes 
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4.3.4 Transformation of competent bacteria  
In order to amplify plasmid DNA, different vectors were transformed into competent bacteria. 
For bacterial transformation, 0.1-50 ng plasmid DNA was added to 50 µl of the respective 
bacterial strain (Table 14). After incubation on ice for 30 minutes, the plasmid/bacteria mixture 
was heated in a 42 °C water bath for 42 seconds, and incubated on ice for 2 minutes. For vectors 
containing kanamycin resistance, transformed bacteria were growing in 900 µl pre-warmed 
Luria-Bertani (LB) media at 37°C for 1 hour with shaking (250 RPM) before inoculation 
Kanamycin-containing (25 µg/ml) agar plate. For vectors with Ampicillin resistance, transformed 
bacteria were inoculated directly on Ampicillin-containing (50 µg/ml) agar plates. After selection 
overnight, single clones were picked for further testing and amplification.  
For long-term storage of transformed bacteria, single clones were picked and incubated in 2 ml 
LB media with respective antibiotics. After growing overnight, 500 μl of the cultured bacteria 
was added to 500 μl glycerol (50%) in a cryovial and storted at -80°C. 
 
4.3.5 DNA purification (MidiPrep and EndoFree Maxiprep) 
For in vitro experiments, midipreps were carried out for the purification of plasmid DNA. Single 
bacterial clones were picked and incubated with 80 ml LB media containing Ampicillin (50 
µg/ml) or Kanamycin (12.5 µg/ml) under shaking at 250 RPM. After overnight incubation, 
cultured bacteria were pelleted down by centrifugation at 5,000 RPM for 10 minutes. Cell pellet 
was resuspended in 3 ml Cell Resuspension Solution. Bacteria were lysed by adding 3 ml Cell 
Lysis Solution and mixed via gentle mixing. After incubation at room temperature for 3 minutes, 
the lysate was neutralized by adding 5 ml chilled Neutralization Solution. The neutralized lysate 
was incubated on ice for 5 minutes to allow sufficient precipitation. Afterwards, cell lysate was 
transferred on a PureYield Clearing Column to remove the precipitate. The clear supernatant was 
added to a DNA Binding Column. The DNA Binding Column was washed 1x 5 ml Endotoxin 
Removal Solution, 2x 20 ml Column Wash Solution. After drying of the DNA Binding Column, 
plasmid DNA was eluted by adding 600 μl nuclease free water and centrifugation at 5,000 RPM 
for 5 minutes.  
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For the purification of plasmid DNA for in vivo experiment, an EndoFree Maxiprep kit was 
applied (Table 6).  Single clones were picked up and incubated in 200 ml LB media containing 
the respective antibiotic overnight with shaking (250 RPM). Purification was performed 
according to the manufacturer’s instructions. Compared to the Midiprep, endotoxin produced by 
bacteria was removed by incubating with 2.5 ml Endotoxin Removal Buffer on ice for 30 
minutes. After elution of plasmid DNA from the column, DNA was precipitated by adding 10.5 
ml isopropanol and centrifuged at 5,000 RPM for 1 hour. Afterwards, the resulting DNA pellet 
was washed with 5 ml of 70% endotoxin-free ethanol, and centrifuged at 5,000 RPM for 40 
minutes. After drying, 600 μl endotoxin-free Buffer TE was added to dissolve the plasmid DNA.  
 
4.4 Messenger RNA (mRNA) quantification 
4.4.1 RNA extraction from cultured cells 
For total RNA extraction from cultured cells, the NucleoSpin RNA II kit was applied according 
to the manufacturer’s instructions. Specifically, cells grown on 6-well plate were lysed by adding 
350 μl Lysis Buffer RA1 with 1% ß-mercaptoethanol. Cell lysate was filtered by loading on a 
NucleoSpin
® 
Filter and centrifuged at 11,000x g for 1 minute. Filtered lysate was mixed with 350 
μl of 70 % ethanol and loaded on a RNA-binding column. After centrifugation at 11,000x g for 
30 seconds, silicon membrane was desalted by adding 350 μl Membrane Desalting Buffer. The 
genomic DNA on silicon membrane was digested with 95 μl DNase reaction mixture at room 
temperature for 15 minutes. Afterwards, the RNA column was sequentially washed with 200 μl 
RAW2, 600 μl RA3, and 250 μl RA3. After each washing step, the column was centrifuged at 
11,000x g for 30 seconds (last step for 2 minutes). RNA was eluted by adding 60 μl RNase-free 
water and centrifugation at 11,000x g for 1 minute. RNA concentrations were determined by 
Nanodrop and stored at -80°C.  
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4.4.2 cDNA synthesis 
Reactions and program for cDNA synthesis are listed in Table 24-25. cDNA was diluted 1:50 for 
further analysis.  
Table 24: Reaction of cDNA synthesis 
Component Amount Final concentration 
Total RNA 1 µg 50 ng/µl 
dNTP (10 mM) 2 µl  1 mM 
Random Hexamer primers (100 µM) 1 µl 5 µM 
5x RT reaction buffer 4 µl  1x 
RevertAid H Minus Reverse Transcriptase 0.9 µl  9 units/µl 
Nuclease free water add to 20 µl - 
 
 
Table 25: Program of cDNA synthesis 
Step Temperature Time Comment 
Denaturation 75 °C 5 minutes 
5x RT reaction buffer was added at the 
end of this step 
Annealing 25 °C 15 minutes 
Reverse Transcriptase was added after 
5 minutes of this step 
cDNA synthesis  42 °C 1 hour - 
Enzyme inactivation 70 °C 10 minutes - 
 
 
 
 
4.4.3 Semi-quantitative real-time PCR analysis 
Real-time PCR reactions were set up using the ABsolute qPCR SYBR Green ROX Mix (Table 
26-27). β2-Microglobulin was used for the normalization of in vitro experiments. StepOnePlus™ 
The standard curve method was used for quantification. Different dilutions of cDNA from 
HepG2 cells (1:12.5, 1:25, 1:50, 1:100, 1:200, and 1:400) were used for generation of the 
standard curves for each primer pair.  
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Table 26: Reaction of real-time PCR 
Component Amount Final concentration 
cDNA (1:50) 2 µl 1:500 
SYBR Green ROX Mix (2x) 5 µl 1x 
Forward primer (10 µM) 0.3 µl 0.3 µM 
Reverse primer (10 µM) 0.3 µl 0.3 µM 
Nuclease free water 2.4 µl - 
 
 
Table 27: Program of real-time PCR 
PCR Cycle Step Temperature Time 
1 Initial denaturation 95 °C 15 minutes 
40 x 
Denaturation 95 °C 15 seconds 
Combined annealing and extension  60 °C 60 seconds 
1 Melting curve 60 °C - 95 °C Increase at 0.5 °C/minute 
 
 
4.4.4 Gene expression profiling 
Affymetrix Human Gene 2.0 ST Arrays were used for the expression analysis of total mRNA 
derived from HepG2 cells stably expressing Scrib
WT
 or Scrib
P305L
. After extraction of total RNA 
from both cell lines, complementary RNA labeled with biotin was prepared according to the 
Affymetrix standard labelling protocol. The complementary RNA was purified, fragmented, and 
hybridized uisng the GeneChip Hybridization oven 640. The arrays were washed and stained 
with the GeneChip Fluidics Station 450, and detected by using the GeneChip Scanner 3000. 
Custom CDF with Entrez-based gene definitions were used for the annotation of the arrays [61]. 
Values from the arrays were rearranged by quantile normalization, and analyzed using the 
software package SAS JMP7. Array data was uploaded in the Gene Expression Omnibus 
database (available: http://www.ncbi.nlm.nih.gov/geo/; accession number GSE93742). 
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4.5 Protein biochemistry analyses 
 
4.5.1 Protein extraction from cultured cells 
Cells on culture plates were washed briefly with ice-cold PBS. A certain volume (80 µl for 6-well 
plate, 300 µl for 10 cm dish) of cell lysis buffer supplemented with Proteinase Inhibitor (1x), 
PMSF (1 mM) and PhosStop (1x) was incubated with cultured cell on ice for 2 minutes. Cell 
lysate was collected and briefly frozen in liquid nitrogen. After thawing, the cell lysate was 
sonicated for ten seconds to shear DNA. Afterwards, the suspension was centrifuged at 14,000 
RPM for 15 minutes. The supernatant containing total proteins were isolated and stored at -20°C 
before analysis. 
 
4.5.2 SDS-Polyacrylamide gel electrophoresis (PAGE) and western immunoblotting 
For western immunoblotting analysis, equal amount of proteins ranging from 30-50 µg were 
prepared in 3x SDS-protein sample buffer and denatured at 95°C for 5 minutes. Protein samples 
were loaded on polyacrylamide gels (8% to 12%) next to 8 µl of a 10-250 kDa Prestained Protein 
Ladder (Table 3). Electrophoresis was carried out with 120 V in electrophoresis buffer for 2 
hours. Proteins on polyacrylamide gel were transferred to a 0.45 µm nitrocellulose membrane 
using a blotting chamber with ice-cold borate buffer at 90 V and 1000 mA/chamber for 1.5 hours.  
After blocking unspecific bands with 5% (w/v) milk powder or 5% (w/v) BSA in TBST (0.1% 
Tween 20 in TBS, v/v) for 1 hour, membranes were incubated with primary antibodies 
(concentrations are listed in Table 7) at 4°C overnight. After incubation, the membranes were 
washed 3x with TBST (0.1%), and incubated with respective fluorophore-labeled secondary 
antibodies (1:20,000; IRDye 680 and 800) at room temperature for 1 hour. After washing 3x 
TBST (0.1%), signals on the membranes were detected using a LI-COR fluorescent imaging 
(Odyssey SA Infrared Imaging System). Actin was used as a loading control. 
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4.5.3 Fractionation of subcellular proteins  
For the fractionation of cytoplasmic and nuclear proteins, a NE-PER™ Nuclear and Cytoplasmic 
Extraction Reagents kit was used. Cells were seeded on 10 cm dishes at high cell density (>80% 
confluence). For experiments with low cell density, 4 dishes were prepared and pooled. 
Fractionation was performed according to the manufacturer’s instructions. After quantification, 
cytoplasmic and nuclear protein extracts were loaded on polyacrylamide gel with the ratio of 2:1 
(cytoplasmic: nuclear fraction) for western immunoblotting (see 4.5.2). β-Tubulin and PARP 
(poly-ADP ribose polymerase) served as loading controls for cytoplasmic and nuclear fractions, 
respectively. 
Membranous and cytoplasmic protein fractionation was performed by using the Mem-PER Plus 
Membrane Protein Extraction Kit. Cells were seeded on 10 cm dishes and fractionation was 
performed according to the manufacturer’s instructions. For western immunoblotting of 
membranous proteins, an antibody detecting Na
+
-K
+
-ATPase was used for a loading control. For 
cytoplasmic proteins, β-Tubulin was used as a loading control.  
4.5.4 Enzyme-linked immunosorbent assay (ELISA) 
Human SPARC Quantikine ELISA kit was used to determine the secreted concentrations of 
SPARC in the supernatant of cultured cells. For this, cells were starved in the respective medium 
without FCS for at least 12 hours. Media (100 µl) from cultured cells were collected from each 
sample and centrifuged for 15 minutes at 1,000x g to remove particles. The resulting supernatants 
were diluted 1:2 in Calibrator Diluent RD6-59. Samples, SPARC standards, and blank control 
(Diluent RD6-59) were incubated in the ELISA microplate at room temperature with 300 RPM 
shaking for 3 hours. After that, wells were washed simultaneously with wash buffer and 
incubated with of human SPARC conjugate antibody (200 µl) in the dark at 4°C for 1.5 hours. 
After an additional washing step, 200 µl of the substrate solution was added. Fluorescence was 
detected using the Fluostar Omega microplate reader at wavelengths of 450 nm and 550 nm. The 
absorbance of 550 nm was subtracted from the absorbance of 450 nm. For each sample and 
standard solution, the respective absorbance was corrected for the blank control. Absolute 
concentrations for SPARC were calculated according to the standard curves of recombinant 
SPARC provided by the manufacturer.  
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4.5.5 Protein half-life determination 
Cycloheximide (CHX) chase analysis was performed to compare protein stability. To define the 
optimal CHX concentration for HepG2 cells, the lowest concentration which efficiently blocked 
protein synthesis was analyzed. Specifically, different amounts of CHX (50, 100, 150, 200, and 
250 μg/ml) were applied to HepG2 cells for 16 hours. Proteins were extracted (see 4.5.1) and 
analyzed by western immunoblotting (see 4.5.2). Measurement of a known unstable protein (e.g. 
c-MYC) revealed that that 100 µg/ml CHX efficiently blocked protein synthesis without killing 
cells in this time-frame.  
For the analysis of PHLPP1 and PTEN stability, HepG2 stable cell lines were seeded with a cell 
density of 8x10
4
/well in a 12-well plate. PHLPP1 with short half-life was chased until 8 hours, 
with 0.5 to 2-hours intervals. PTEN with longer half-life was chased until 72 hours, with 2 to 8-
hours intervals. Protein extracts from each time points were collected and analyzed by western 
immunoblotting (see 4.5.2). The relative protein amounts for PHLPP1 and PTEN were quantified 
compared to the original protein levels at time-point '0'. Image Studio software was employed for 
the quantification of proteins. 
 
4.5.6 Immunofluorescence analysis of tissue cryosections  
A methanol-acetone fixation method was used for immunofluorescence stains of cryosections 
derived from human livers. Tissues were fixed in ice-cold methanol for 5 min followed by ice-
cold acetone for 1 min on ice. The permeabilization step was performed by incubation with 
Triton X-100/PBS (0.2%, v/v) at room temperature for 5 min. For blocking, tissue sections were 
incubated with BSA/PBS (1%, w/v) for 30 min. Samples were then incubated with primary 
antibodies (listed in Table 7) in a wet chamber at 4°C overnight. After three times of wash with 
PBST (0.01%, Tween in PBS, v/v), tissue sections were incubated with the respective secondary 
antibodies in a wet chamber for 1 hour. After washing 3x with PBST, and rinsed with distilled 
water, cryosections were dehydrated with 100% ethanol. The visualization of nuclei and tissue 
mounting were achieved by the incubation with DAPI Fluoromount-G.  
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4.5.7 Immunofluorescence analysis of sandwich cultures 
For the visualization of polarity markers in sandwich cultures, a published hepatocyte sandwich 
immunofluorescence staining method was modified [62]. In brief, sandwich cultures were 
prepared on coverslips in cell culture plates for 1-2 weeks. After washing 1x with MgCl2/PBS 
(2mM), the sandwich cultures were fixed with PFA solution (4%, w/v) at room temperature for 
20 minutes. This was followed by a permeabilization step with Triton/PBS (0.5%, v/v) at room 
temperature for 10 minutes. Afterwards, the coverslips were thoroughly washed 3x with PBS at 
room temperature (2x 5 minutes followed by additional 30 minutes). After blocking with 
BSA/PBS (5%, w/v) for 30 minutes, the coverslips were washed with PBST (0.05% Tween in 
PBS, v/v) and transferred into a wet chamber. On each slide 150-200 µl primary antibodies 
(Table 7) were incubated at 4°C, overnight. After primary antibody incubation, sandwiches were 
washed 3x with PBST at room temperature for 10 minutes followed by an incubation with 200 µl 
secondary antibodies at room temperature in a dark chamber for 2 hours. After incubation, the 
sandwich cultures were washed 3x with PBST for 10 minutes, and 3x with PBS for 10 minutes. 
Eventually, the sandwich cultures were dehydrated with 100% ethanol, and mounted by a DAPI 
Fluoromount-G. 
4.5.8 Immunohistochemistry (IHC) and histological analyses 
Paraffin embedded tissues were cut in 2-3 µm sections using a microtome and dried overnight. 
Tissues were deparaffinised by 3x incubation with xylene for 5 minutes. Afterwards, sections 
were rehydrated using an ethanol gradient (2x 100% Ethanol, 96% Ethanol, 70% Ethanol, water 
each 2 min). For antigen retrieval, tissue sections were incubated with 10 mM citrate buffer (pH 
6.0) in a stream cooker. After cooling down, tissues were blocked with avidin and biotin at room 
temperature for 30 minutes (Avidin/Biotin Blocking Kit), and incubated with primary antibodies 
(Table 7) in a wet chamber at 4°C overnight.  
For E-cadherin, ATF2, and pAKT stains, AP (alkaline phosphatase)-based DCS Detection Line 
system was employed. For this, tissue sections were incubated with Rabbit Enhancer for 20 min, 
and incubated with AP-Polymer Detection Line for further 20 min. After washing 2x with TBS 
for 5 minutes, sections were incubated with Permanent AP Red. For Scrib and MCAM stains, the 
horseradish peroxidase (HRP) system was used. Tissues were blocked with H2O2 for 10 min, and 
incubated with biotinylated secondary antibody for 30 min. This was followed by incubation with 
Streptavidin-HRP for 20 min and signal development with DAB (for Scrib stain) or AEC (for 
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MCAM stain). After washing 2x with TBS for 5 minutes, tissue sections were incubated with 
REAL Hematoxylin for nuclear visualization. All stains were performed by the IHC research 
facility at the Institute of Pathology, Heidelberg.  
For histological analysis of liver tissues, Hematoxylin and eosin (H&E) stains from each tissue 
samples were analyzed by pathologist. Tumors were identified by well-vascularized nodules with 
necrotic areas within the tumor mass. Tumor cells were identified with a pleomorphic shape, a 
basophilic cytoplasm and sometimes fat droplets. In addition, hyperchromatic nuclei with 
increased nuclear to cytoplasmic ratio were presented in the tumor cells. Immunohistochemistry 
stain of Ki-67 was used to detect the increased mitotic activity of tumor cells.  
 
4.6 Immunoprecipitation analysis 
4.6.1 Co-Immunoprecipitation (CoIP) analysis 
For the detection of specific protein-protein interactions, CoIP experiments with Protein A/G 
beads and magnetic separation were performed [63]. A 12-Tube magnet was used to capture the 
antibody-bound protein complexes. In brief, cells grown on a 10 cm dish were lysed with 300 µl 
ice-cold non-denaturing lysis buffer supplemented with protease inhibitors (3 µl). The 
supernatant was collected after centrifugation at 14,000x g for 10 minutes. In total, 20 µl of 
protein lysate were preserved as Input control. Dynabeads Protein G beads (50 µl) were 
incubated with 50 µl glycine solution (50 mM) for at room temperature for 5 minutes. After 
removing glycine solution from the Dynabeads, primary antibodies (2 µg) were pre-incubated 
with Dynabeads Protein G at 4°C for 4 hours under rotation. After two washing steps with PBST, 
the coupled antibody-Protein G beads were incubated with 1 mg protein lysate (defined by 
Bradford assay) under rotation at 4°C overnight. An equal amount of rabbit IgG antibody (2 µg) 
incubated with Dynabeads and eand quivalent amount of protein lysate were used as negative 
control. After incubation, Dynabeads-protein complexes were washed 3x with PBS using the 
magnet. After washing, the complexes were resuspended in 100 µl PBS and transferred in new 2 
ml-tubes. The bound proteins were eluted from the Dynabeads by incubation with Laemmli 
buffer (2x concentrated, 30 µl) at 95°C and vortexing for 15 min. The supernatant containing 
denatured proteins were analyzed by western immunoblotting analysis (see 4.5.2).  
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4.6.2 Chromatin-Immunoprecipitation (ChIP) analysis 
ChIP analysis was carried out to detect the interactions between transcription factors and specific 
promoter regions. For this, 1.1x10
7
 cells were seeded on 15 cm dishes and cultured for 2 
additional days. DNA and proteins were cross-linked using 20 ml of formaldehyde/PBS (1%) for 
12 min, followed by quenching with 1 ml of glycine (2.5 M) for 5 min. After washing with ice-
cold PBS, cells were lysed with 1 ml ice-cold RIPA buffer on ice. The DNA fragments (500 bp-1 
kb) were generated by sonication (amplitude 15, power level 1.5) for 2 minutes. Cell debris was 
removed by centrifugation at 16,000x g at 4°C for 15 minutes. Protein concentrations were 
determined by Bradford assay and equalized to 1 mg/ml with RIPA buffer. Diluted cell lysate 
was pre-cleared with 30 µl of Dynabeads Protein G. In parallel, 50 µl Dynabeads Protein G beads 
was blocked with salmon sperm DNA (15 µg) and BSA (50 µg) for 2 hours. Pre-cleared samples 
were incubated with blocked Dynabeads and respective antibodies (4 µg) at 4°C overnight. The 
resulting immunocomplex-bound-beads were washed 4x with RIPA buffer, 2x with IP wash 
buffer and again 2x with RIPA buffer (for 5 min each). The Dynabeads complexes were 
resuspended in 100 µl TE buffer. Immunocomplexes were eluted with 200 µl of Talianidis 
elution buffer (1.5x concentrated) at 65°C for 15 min. Reversal crosslinking was achieved by 
adjusting to 200 mM NaCl (4 M) and incubation at 65°C for 5 hours. DNA was extracted by the 
PCR Clean-Up kit according to the manufacturer's protocol. Real-time PCRs were performed to 
determine the quantity of precipitated promoter fragments with the normalization to a standard 
curve derived from serial dilutions of genomic DNA. As a negative control, primers binding to 
5,200 bp downstream of the start codon was used. 
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4.7 Mouse work 
The experimental setup and group size were approved by the German Regional Council of 
Baden-Wuerttemberg (ref. number: G-30/16; Karlsruhe, Germany) and in accordance with the 
institutional regulations of the Interfakultäre Biomedizinische Forschungseinrichtung (IBF), 
University of Heidelberg, Germany). Exclusion and termination criteria are defined in the ATBC 
criteria of the animal welfare officer of the University Hospital Heidelberg.  
 
4.7.1 Hydrodynamic tail-vein (HDTV) plasmid delivery 
A HDTV gene delivery method was employed to analyze the effect of cytoplasmic and 
membranous Scrib on liver tumor development. The establishment of HDTV is based on the 
anatomical structure of the liver, which is highly permeable between sinusoids and liver 
parenchymal cells (Chapter 1.1.1). The large volume of plasmid DNA solution flowing into vena 
cava inferior induces cardiac congestion, which leads to the enrichment of plasmids in the veins 
of mouse liver. This allows the penetration of injected plasmid DNA from blood vessels into 
hepatocytes under physical pressure. In order to allow a permanent integration and expression of 
target genes, a Sleeping Beauty transposon (SB) system was used to mediate genomic integration 
of the pT3-EF1α vectors [64]. The pT3-EF1α-c-MYC (12.5 μg) vector was combined with pT3-
EF1α-hScribWT-GFP or pT3-EF1α-hScribP305L-GFP (12.5 μg) plasmids and mixed with SB (5 
μg) in 2 ml (approximately 10% of animal body weight) sterile PBS for each mouse. Before 
injection, plasmid solutions were pre-warmed at 37´°C in a water bath and transferred in a 2 ml 
syringe. For injection, FVB/N mice at the age of 10 weeks were fixed in a mouse restrainer. 
Plasmid solution was injected into the lateral-tail vein within 7-10 seconds. As a control, pT3-
EF1α-c-MYC (12.5 μg) vector combined with pT3-EF1α-GFP (12.5 μg) was injected. The 
transient transfection efficiency can be analyzed 48 hours after injection by IHC stains of GFP. 
However, because the SB-induced genomic integration was applied in this technique, stable 
expression of transgenes was analyzed 2 weeks after injection. 
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4.7.2 Isolation of mouse liver tissue  
Four weeks after HDTV, liver tissue was isolated from injected mice for protein and histological 
analysis. The mice were sacrificed by CO2 asphyxiation. The abdominal cavity was carefully 
opened with a surgical scissor; the gastric system was removed to the right side. The ligaments on 
the anterior and superior liver surface were separated from the diaphragm. Afterwards, the mouse 
liver was slightly removed from the porta hepatis using a surgical tweezer. The inferior surface 
of liver was carefully separated from abdominal organs. The isolated livers were briefly washed 
with PBS, and put on a 10 cm cell culture dish. Individual lobes were separated using a surgical 
scalpel (blade #22).  
The isolated liver tissues were immediately fixed in buffered formalin for 2 days followed by 
IHC staining (Chapter 4.5.8). In addition, small pieces of liver tissues were transferred into 
Precellys tubes and transferred to liquid nitrogen for protein and RNA purification. The methods 
for protein and RNA extraction are described in 4.5.1 and 4.4.1 respectively. For long-term 
storage, the protein and RNA samples were stored at -80°. Representative IHC photos from 
isolated livers showing the Scrib-positive cells 2 days after injection are presented in Figure 7. 
 
Figure 7: Transient transfection of pT3-EF1α-hScrib
P305L
-GFP plasmid in mouse liver. A mouse liver was 
collected 2 days after the HDTV injection of pT3-EF1α-hScrib
P305L
-GFP and pT3-EF1α-c-MYC plasmids. The 
mouse liver was fixed in buffered formalin for 2 days, and continued with IHC stains of Scrib. Positive cells 
with transient Scrib expression (indicated by arrows) were observed surrounding the veins of liver. Photos were 
taken under 40x magnification, with scale bar: 500 μm; and 100x magnification, with scale bar: 200 μm.  
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4.8 HCC Patient material 
 
4.8.1 HCC patient gene expression and survival data 
Transcriptome and clinical data derived from 249 primary HCCs and corresponding non-
tumorous liver tissues were used for this study [65]. Expression levels of 33 polarity genes were 
compared between HCCs (n=249) and non-tumor livers (n=239). Overall survival and 
recurrence-free survivals of HCC patients (n=242) were analyzed using Kaplan-Meier curves and 
statistically compared using the Log-Rank Test. Chromosomal gains and losses were calculated 
by analyzing CGH array data derived from 60 HCC patients out of the transcriptome cohort [66]. 
In order to characterize the subcellular localization of Scrib in tissues, cryo-conserved non-
tumorous livers (n=20) as well as HCC tissues (n=32) were obtained from the NCT tissue bank 
Heidelberg (application no. 1921). The project was approved by the ethics committee of 
Heidelberg University. 
 
4.8.2 HCC tissue-microarray (TMA) analysis 
The TMA used for IHC analysis consisted of non-tumor livers (n=7) and HCC tissues (n=105). 
The histological grading of HCC tissues was done by an experienced hepato-pathologist (G1=10, 
G2=75, G3=16, G4=4). Immunohistochemistry stains were analyzed according to both 
quantitative and qualitative parameters. For quantitative parameter, number of cells was 
analyzed: 0=no positive cells, 1=less than 1%, 2=less than 10%, 3=10-50%, 4=more than 50%. 
For qualitative parameter, staining intensity was analyzed: 0=negative, 1=low, 2=medium, 
3=strong. The final score was given by multiplying quantitative and qualitative parameters. 
Evaluation was done by two experienced investigators. 
  
METHODS 
 
52 
 
4.9 Data acquisition and statistical analysis 
Data are presented as mean ± standard deviation. IBM SPSS Statistics (21.0, Armonk, NY, USA) 
was used to perform statistical analysis. The Mann-Whitney U test was used to compare 
nonparametric variables between two independent groups. The Spearman rank coefficient test 
was used to find associations between variables. Patient survival and recurrence data were 
analyzed by the Log-Rank Test. All in vitro experiments were repeated 2-3 times. 
Best Cutoff Finder was applied to define two groups of patients for survival analysis [67]. 
JASPAR data base was used to identify the potential AP1 family binding site on SPARC 
promoter region [68]. ImageJ software was used to add scale bars for photos. Adobe Photoshop 
CS5 was employed for the design and alignment of figures.  
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5 RESULTS 
 
5.1 Overexpression of Scrib is associated with poor survival in 
HCCs 
The hypothesis of this study was that dysregulation of single molecules of EPP system, 
which leads to a functionally disturbance of hepatocyte polarity, may also play an 
important role in the process of HCC development. In order to identify functionally 
relevant factors, mRNA expression data of polarity proteins were analyzed in a HCC 
cohort of 249 patients [65].  Candidate polarity genes included 33 different factors, which 
belong to the three major polarity complexes: Crumbs complex, PAR complex, and Scrib 
complex. Additional genes (e.g. CTNNA1 and CTNNB1) are closely related to cell-cell 
junctions. The selection criteria were (1) overexpression of the polarity gene in HCC 
tissues compared to the surrounding liver tissues; (2) expression level of candidate gene 
was associated with both overall survival and recurrence-free survival of HCC patients. 
Among the 33 polarity genes, six genes achieved these criteria: CDC42, CTNNA1, 
DLG5, MPP5, SCRIB and TJP1. A summary of the expression and survival data from all 
the 33 polarity genes is listed in Table 28. The comparisons of mRNA expressions 
between livers and HCCs, as well as the Kaplan-Meier survival curves for the six 
candidate genes are shown in Figure 8. 
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Table 28: Analysis of 33 polarity genes in human HCC and liver tissues 
Gene 
Symbols 
Gene Names 
HCCs compared 
to livers 
Survival 
correlation 
Recurrence 
correlation 
AMOT Angiomotin Underexpressed Yes No 
AMOTL2 Angiomotin like 2 Underexpressed No No 
CDC42 Cell Division Cycle 42 Overexpressed Yes Yes 
CDH1 Cadherin 1 Underexpressed Yes Yes 
CLDN1 Claudin 1 ns No No 
CRB1 Crumbs 1, Cell Polarity Complex 
Component 
ns No No 
CTNNA1 Catenin Alpha 1 Overexpressed Yes Yes 
CTNNB1 Catenin Beta 1 Overexpressed No No 
DLG1 Discs Large MAGUK Scaffold Protein 1 Overexpressed No Yes 
DLG2 Discs Large MAGUK Scaffold Protein 2 Underexpressed Yes* No 
DLG3 Discs Large MAGUK Scaffold Protein 3 Underexpressed No No 
DLG4 Discs Large MAGUK Scaffold Protein 4 Underexpressed Yes No 
DLG5 Discs Large MAGUK Scaffold Protein 5 Overexpressed Yes Yes 
INADL 
PATJ, Crumbs Cell Polarity Complex 
Component 
Underexpressed No No 
LIN7C 
Lin-7 Homolog C, Crumbs Cell Polarity 
Complex Component 
Underexpressed Yes Yes 
LLGL1 Lethal Giant Larvae Homolog 1 Underexpressed Yes Yes 
LLGL2 Lethal Giant Larvae Homolog 2 Overexpressed No no 
MPP1 Membrane Palmitoylated Protein 1 Underexpressed No Yes 
MPP5 Membrane Palmitoylated Protein 5 Overexpressed Yes Yes 
PARD3 Par-3 Family Cell Polarity Regulator Overexpressed No No 
PARD6A Par-6 Family Cell Polarity Regulator 
Alpha 
Underexpressed No No 
PARD6B Par-6 Family Cell Polarity Regulator Beta Underexpressed No No 
PRKCZ 
 
Protein Kinase C Zeta 
 
Underexpressed No No 
SCRIB Scribbled Planar Cell Polarity Protein Overexpressed Yes Yes 
TJP1 Tight Junction Protein 1 Overexpressed Yes Yes* 
TJP2 Tight Junction Protein 2 Underexpressed Yes No 
WWC1 
 
WW And C2 Domain Containing 1 
 
Overexpressed No No 
CRB2 
 
Crumbs 2, Cell Polarity Complex 
Component 
 
ns No No 
CRB3 
Crumbs 3, Cell Polarity Complex 
Component 
ns No No 
MPP4 
 
Membrane Palmitoylated Protein 4 
 
ns No No 
MPP7 
 
Membrane Palmitoylated Protein 7 
 
ns No No 
PARD6G 
 
Par-6 Family Cell Polarity Regulator 
Gamma 
 
ns No No 
AMOTL1 Angiomotin like 2 ns No No 
* Small group size according to the “Cutoff Finder”. Bold characters: genes significantly overexpressed in 
HCC patients and associated with poor overall survival and cancer recurrence. 
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Figure 8: Polarity gene expression of five candidate polarity genes correlated with HCC patient 
survivals.  (A) Gene transcriptome analysis of Scrib mRNA levels in HCC tissues (n=247) compared 
to non-tumor liver tissues (n=239). Cutoff value (Log2 mRNA expression) was 6.742 for overall 
survival, and 6.879 for recurrence free survival. (B) For CDC42, cutoff value was 5.56 for both 
overall and recurrence free survivals. (C) For CTNNA1, cutoff value was 6.55. (D) For DLG5, cutoff 
value was 4.90. (E) For MPP5, cutoff value was 3.96. (F) For TJP1, cutoff value was 5.45. The log-
rank test was used for the statistical comparison of groups. 
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Among the 6 polarity genes, MPP5 and TJP1 were moderately but significantly 
overexpressed in the group of HCCs. Nevertheless, this elevated expressed of MPP5 and 
TJP1 was associated with better patient survival (Figure 8 E/F). Notably, Scrib showed 
the strongest induction (2.14-fold) in HCC tissues compared to surrounding liver tissues. 
In addition, its overexpression showed the strongest association with poor overall and 
recurrence-free survival. For this reason and because the functional impact of Scrib 
overexpression was never systematically analyzed in HCC, Scrib was selected for further 
analysis. 
In order to find out if the overexpression of Scrib in HCCs was due to genomic 
alterations, the mRNA expression data derived from human HCCs was compared with 
array-based comparative genomic hybridization (array-CGH) data [66]. In an aCGH data 
subset of 60 patients, amplifications of Scrib at the gene locus (chr. 8q24.3) were 
detected in 11 patients.  Indeed, the Scrib mRNA expression levels in these patients with 
chromosomal gains were significantly elevated in comparison to patients without 
genomic alterations (Figure 9), suggesting that the gains might be causative Scrib 
overexpression in some HCCs. 
 
 
 
Figure 9: Scrib overexpression was associated with 
chromosome gains. Scrib mRNA levels were 
compared between HCC samples with chromosomal 
gains (n=49), and without chromosomal gains (n=11). 
The Mann–Whitney U test was used for statistical 
comparison. 
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5.2 Mislocalization of Scrib in HCC tissues and cell lines  
Scrib is overexpressed in human HCC tissues and elevated Scrib levels may be due to the 
genetic amplifications. Interestingly, the mislocalization of Scrib has also been described 
in breast cancer patients [42]. For this reason, I hypothesized that also the localization of 
Scrib may play a role in the process of HCC development.  
In order to characterize Scrib localization in human livers and HCCs, 
immunofluorescence stains of Scrib were carried out using cyosections from healthy 
livers (n=20), as well as HCC tissues (n=32). A clear membranous Scrib localization was 
observed in most (90%) healthy liver tissues (Figure 10A).  In contrast, a frequent 
cytoplasmic Scrib mislocalization was found in the majority of HCC tissues (69%). In 
tissues with Scrib mislocalization, about 50% of patients had a partial loss of 
membranous Scrib, while other patients showed a complete membranous loss and 
cytoplasmic enrichment of Scrib (Figure 10B). 
 
 
Figure 10: Mislocalization of Scrib in HCC tissues. (A) Representative pictures of Scrib 
immunofluorescence stains from healthy livers and HCCs. In normal livers, 90% (18/20) of all 
analyzed samples showed a clear membranous Scrib localization. In HCCs, most of the cases 69% 
(22/32) had a cytoplasmic localization of Scrib. Scale bars: 200 µm. (B) Quantification of Scrib 
localization in healthy livers and HCCs. The relative amount of cytoplasmic Scrib is significantly 
higher in HCC tissues compared to healthy livers. Fisher's exact test was performed (P≤0.001).  
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In order to test for suitable in vitro models for further studies, the expression and 
localization of Scrib were compared in different HCC cell lines (HepG2, HuH1, Huh6, 
Hep3B, HLF and HuH7). The mRNA levels of Scrib were higher in most HCC cell lines 
compared to the immortalized hepatocytes (THLE-2), (Figure 11A). Protein analysis 
confirmed higher Scrib expression in HCC cell lines compared to the non-malignant cell 
line. Highest Scrib protein levels were detected in HepG2, HuH6, HLE and HLF cells 
(Figure 11B). To gain further insight into Scrib localization in HCC cell lines, 
immunofluorescence of Scrib was carried out in lines with higher protein abundance. 
HepG2, HuH1 and HuH6 showed a clear membranous localization, while Hep3B, HLF 
and HuH7 showed a predominately cytoplasmic localization (Figure 11C). These data 
illustrate that next to overexpression, Scrib is also localized in the cytoplasm in a 
subgroup of HCC cell lines.  
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Figure 11: Different expression and localization of Scrib in HCC cell lines. (A) Comparison of 
Scrib mRNA levels in different HCC cell lines (HepG2, Huh1, Huh6, Huh7, Hep3B, HLE, HLF, and 
SNU182) and non-malignant THLE-2 cells by real-time PCR. (B) Comparison of Scrib protein levels 
in HCC cell lines and THLE-2 cells using Western immunoblotting. Actin served as the loading 
control. (C) Immunofluorescence analysis reveals differential localizations of Scrib in human HCC 
cell lines. Magnification: 400-fold, scale bars: 40 μm.  
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5.3 Scrib localization affects hepatocellular polarity  
In order to study the impact of cytoplasmic Scrib in HCC cells, two cell lines stably 
expressing the wildtype (Scrib
WT
) and mutated Scrib (Scrib
P305L
) were generated. The 
P305L mutation in the leucine-rich repeats (LRR) domain abrogates the binding of Scrib 
with other cell polarity factor leading to its enforced cytoplasmic localization [69]. 
Plasmids coding for EGFP-tagged Scrib
WT 
and Scrib
P305L 
were transfected into HepG2 
cells, which showed a polarized phenotype as well as a membranous localization of Scrib 
(Figure 11C). Cell lines stably expressing Scrib
WT
 or Scrib
P305L
 were generated and tested 
for the localization of exogenous Scrib by immunofluorescence. As expected, Scrib
WT 
localized specifically to the plasma membrane, whereas Scrib
P305L
 predominantly 
accumulated in the cytoplasm (Figure 12A). The localization of both Scrib isoforms was 
confirmed by Western immunoblotting using membranous and cytoplasmic protein 
fractions (Figure 12B).   
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Figure 12: HepG2 stable cell lines with membranous and cytoplasmic Scrib. (A) 
Immunofluorescence of HepG2 cells stably expressing EGFP-tagged Scrib
WT
 and Scrib
P305L
. Upper 
right corner show higher magnifications to illustrate the expected subcellular Scrib localization. Scale 
bars: 40 µm. (B) Western immunoblots of protein fractions extracted from Scrib
WT
 and Scrib
P305L
 
expressing cells confirm the membranous localization of Scrib
WT
 and cytoplasmic localization of 
Scrib
P305L
. Na
+
-K
+
-ATPase and ß-tubulin served as the loading controls for membranous and 
cytoplasmic proteins fractions, respectively.  
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Interestingly, cell lines stably overexpressing Scrib
WT 
and Scrib
P305L 
showed different 
morphologies when grown on a plastic surface. The Scrib
WT
 cells established a columnar 
shape and compact multilayer colonies, while the Scrib
P305L
 cells acquired a flattened 
shape and a monolayer growth pattern (Figure 13A), which is indicative for disturbed 
cell-cell contact. In order to further analyze the impact of membranous or cytoplasmic 
Scrib on the 3-dimensional hepatocellular structure, a hepatocyte sandwich culture 
containing two layers of collagen matrix was used, which allows the formation of highly 
polarized cells in vitro [6]. After seeding the both cell lines under sandwich culture 
conditions for one week, the cell layers were stained for multidrug resistance-associated 
protein 2 (MRP2), which is a marker for the canalicular network. Elongated canalicular 
structures were detected in Scrib
WT
 cultures, while only spherical and shortened 
structures were found in Scrib
P305L
 cultures (Figure 13B). These results indicate that the 
proper localization of Scrib is critical for the maintenance of hepatocellular polarity.  
 
Figure 13: Disturbance of cell polarity by overexpression of cytoplasmic Scrib
P305L
. (A) Bright 
field photos of HepG2 cells stably expressing Scrib
WT
 and Scrib
P305L
 indicate differences in cell 
morphology and cell-cell contact. Low magnification: 100-fold, scale bar: 200 µm; High 
magnification: 400-fold, scale bar: 40 µm. (B) Sandwich culture stains of MRP2 in Scrib
WT
 and 
Scrib
P305L
 expressed HepG2 cells. Cell lines were seeded at a cell density of 400,000 cells per 6 cm 
dish between collagen sheets for one week. Immunofluorescence stains of MRP2 were performed to 
detect the presence of canalicular structures. Magnification: 400-fold, Scale bars: 40 µm.  
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5.4 Cytoplasmic Scrib induces cell invasion in HCC cell lines 
The initial correlation of Scrib expression and HCC patient data revealed an association 
of Scrib abundance and tumor prognosis. In addition, immunofluorescence illustrated the 
cytoplasmic localization of Scrib in many HCC tissues. In order to find out how 
cytoplasmic Scrib affects liver cancer progression, functional analyses including cell  
viability, apoptosis, and invasion assays were performed with Scrib
WT
 and Scrib
P305L
-
positive HepG2 cells. 
The cell viability assay revealed that cytoplasmic Scrib
P305L
 induced cell viability (Figure 
14A), while membranous Scrib
WT 
did not affect viability for up to 48 hours. In addition, a 
cell cytotoxicity assay illustrated that membranous Scrib
WT
 was associated with increased 
cell cytotoxicity (Figure 14B), while Scrib
P305L 
only moderately increased cell death in 
comparison to untransfected HepG2 cells. To further test if the increase of cytotoxicity 
was due to apoptosis and if Scrib with membranous and cytoplasmic localizations can 
differently affect drug-induced cell death, a caspase-3 activity assay was performed with 
both cell lines. Interestingly, the basal caspase-3 activity was not different between 
Scrib
WT
 and Scrib
P305L
 cells, however, cells expressing Scrib
P305L
 showed relatively lower 
caspase-3 activity after Doxorubicin treatment (Figure 14C). These data illustrate that 
cytoplasmic Scrib moderately affects cell apoptosis and that it may protect hepatocyte 
from cytotoxic challenges. 
Because Scrib overexpression significantly correlated with cancer recurrence in HCC 
patients, additional cell invasion assays were performed.  HepG2 cells stably expressing 
Scrib
WT
 showed a low invasive capacity. In contrast, cells stably expressing Scrib
P305L
 
had a significantly higher invasive capacity (Figure 14D).  
Together, the functional analyses revealed that cytoplasmic Scrib predominantly supports 
HCC cell mobility and invasion and to a lesser extent cell viability and apoptosis.   
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Figure 14: Functional analyses of HepG2 cells with membranous and cytoplasmic Scrib. (A) Cell 
viability of untransfected HepG2 and HepG2 cells expressing Scrib
WT
 or Scrib
P305L
 were measured 24 
and 48 hours after seeding. (B) Cell cytotoxicity assay of untransfected HepG2 and cells expressing 
Scrib
WT
 or Scrib
P305L
 were performed 24 and 48 hours after seeding. (C) Scrib
WT
 and Scrib
P305L
 
expressing HepG2 cells were treated with Doxorubicin (1 µM) for 24 hours followed by measurement 
of caspase-3 activity. Cell lysate were incubated with caspase-3 substrate for 4 hours. (D) HepG2 cells 
expressing Scrib
WT
 and Scrib
P305L
 were analyzed using Transwell chambers with Matrigel-coated 
inserts. The number of transmigrating cells was counted 72 hours after seeding. For each assay, cells 
were counted in seven different visual fields (40-fold magnification). Photos were taken with 100-fold 
magnification. Scale bars: 250 µm. For statistical testing, the Mann-Whitney U Test was used.  
 
 
Because GTPases play an essential role in regulating actin filament in cells which 
undergo EMT (see Chapter 1.2.3), cytoplasmic Scrib may interaction with GTPases in 
the regulation of cell invasion. To further figure out the reasons why cytoplasmic Scrib 
induced HCC cell invasion/migration, the Scrib
WT
 and Scrib
P305L
 cell lines were analyzed 
with regard to their actin organization as well as the content of Rho family GTPases 
using immunofluorescence and Western immunoblotting. Indeed, obvious differences 
were found in case of the actin filament organization. Cells expressing Scrib
P305L
 showed 
clear actin bundles at the leading and trailing edges, which has been regarded as the 
typical structure of actin cytoskeleton in invading/migrating cells [70]. Such actin 
filament structure was less obvious in cells expressing Scrib
WT 
(Figure 15A). Differences 
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regarding the expressions of Rho family GTPases were also detected in the both stable 
cell lines.  Rac 1/2/3 and CDC42, which were strong inducers of cell invasion/migration, 
were increased in cells expressing Scrib
P305L
. However, the negative regulator of cell 
invasion/migration, RhoA, was not differentially expressed in both cell lines (Figure 
15B).  
In summary, these data strongly suggest that cytoplasmic Scrib predominantly supports 
HCC cell mobility and invasion via the regulation of actin filaments and Rho GTPases.   
 
Figure 15: Effects of Scrib
P305L
 on actin filament and Rho GTPases. (A) Immunoflurescence stains 
of actin in cell lines stably expressing Scrib
WT 
or Scrib
P305L
 indicate differential cytoskeleton 
organization. Cells were documented with 400-fold magnification. Scale bars: 40 μm. (B) Western 
immunoblot analysis of Rho-GTPase family proteins in cells with Scrib
WT 
or
 
Scrib
P305L 
expression. 
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5.5 Cytoplasmic Scrib induces tumor formation via AKT 
signaling  
In the next step, we wanted to identify the relevant signaling pathways that were induced 
by cytoplasmic Scrib. Previous studies already demonstrated the regulatory effects of 
Scrib on extracellular signal-regulated kinases (ERK) and Hippo pathway activity [50, 
71]. We first tested if the transcriptional downstream effector of the Hippo pathway YAP 
was affected by the cytoplasmic Scrib
P305L
 in comparison to membranous Scrib
WT
. 
Because YAP phosphorylation regulates its subcellular localization, the phospho-status of 
YAP was considered to be a good read-out for the Hippo/YAP pathway activity [46]. 
However, no difference regarding YAP phosphorylation was observed in HepG2 cells 
stably expression both Scrib isoforms (Figure 16A). In addition, the localization YAP and 
its paralogue TAZ after siRNA-mediated inhibition of Scrib in untransfected HepG2 cells 
was analyzed. Again no nuclear enrichment of YAP or TAZ was detected after Scrib 
silencing (Figure 16B). These results indicate that no direct effect of Scrib on Hippo/YAP 
pathway activity is detectable in HCC cells.  
In the next step, other signaling pathways (ERK1/2, JNK and AKT pathways) that may 
be affected by Scrib were analyzed. In HepG2 cells stably expressing Scrib
WT 
or 
Scrib
P305L
, neither the ERK1/2 nor the JNK pathways were significantly regulated by the 
different Scrib isoforms (Figure 16C). However, the AKT/mTOR pathway was obviously 
induced by cytoplasmic Scrib. Phosphorylation of AKT and its downstream target 
phospho-S6 protein were both induced in cells expressing Scrib
P305L 
in comparison to 
cells with Scrib
WT
 expression (Figure 16C). In order to test if the induction of AKT 
depends on its physiological regulator phosphoinositide 3-kinases (PI3K), PI3K activity 
was inhibited by using Wortmannin. AKT activation was blocked under high dose (0.5 
μM) in both tested cell lines. However, using lower doses (0.05-0.25 μM), Wortmannin 
completely blocked AKT phosphorylation in cells expressing Scrib
WT
, but not in cells 
expressing Scrib
P305L 
(Figure 16D). These results illustrate that AKT/mTOR pathway was 
activated by the overexpression of cytoplasmic Scrib in a PI3K-independent manner.  
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Figure 16: Cytoplasmic Scrib activates the AKT/mTOR pathway. (A) Western immunoblot 
analysis illustrate that neither total YAP nor phospho-YAP are differentially expressed in Scrib
WT 
and 
Scrib
P305L
 cells. (B) siRNA-mediated Scrib inhibition cannot induce the nuclear enrichment of YAP or 
its paralogue TAZ in HepG2 cells. Proteins from cytoplasmic and nuclear fractions were isolated 60 
hours after siRNA treatment. PARP and ß-tubulin served as the loading controls for nuclear and 
cytoplasmic protein fractions, respectively. UTC: untreated cell, NS: non-sense siRNA. (C) Western 
immunoblot of protein lysates derived from Scrib
WT
 and Scrib
P305L
-expressing HepG2 cells shows 
increased phosphorylation of AKT and its downstream target S6 protein in the cells expressing 
Scrib
P305L
. (D) Western immunoblot analysis of Wortmannin-treatment cells illustrates the PI3K-
independent activation of the PI3K/AKT pathway in cells stable stably expressing Scrib
P305L
. DMSO: 
DMSO-treated cells.   
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5.6 Cytoplasmic Scrib destabilizes the phosphatases PTEN and 
PHLPP1 
To further define the molecular mechanism how cytoplasmic Scrib activates the 
PI3K/AKT pathway, two PI3K phosphatases: phosphatase and tensin homolog (PTEN) 
and PH domain leucine-rich repeat-containing protein phosphatase 1 (PHLPP1) were 
chosen as candidates for further analysis. Previous studies already illustrated an 
interaction between Scrib and PTEN in breast cancer cells and between Scrib and 
PHLPP1 in colon cancer cells [42, 72]. For this reason, I hypothesized that cytoplasmic 
Scrib activates PI3K/AKT pathway via physical interactions with PHLPP1 or PTEN in 
HCC cells. Interestingly, Co-IP experiments confirmed the bindings of both Scrib 
isoforms (Scrib
WT
 and Scrib
P305L
) with both phosphatases (PHLPP1 and PTEN). 
However, no significant difference in the binding capacity was detectable, indicating that 
Scrib localization did not change the binding properties with PHLPP1 and PTEN (Figure 
17A, B).  
Because the Scrib localization did not affect PTEN/PHLPP1 binding, it was interesting to 
analyze if and how both phosphatases were involved in the regulation of AKT in HepG2 
cells. To first confirm the inhibitory effect of PHLPP1 and PTEN on AKT 
phosphorylation and activity, a siRNA-mediated knockdown of PHLPP1, PTEN and both 
phosphatases was carried out. Silencing of PTEN or PHLPP1 resulted in a 1.6-fold and a 
1.2-fold increase in phospho-AKT, respectively. The strongest effect on AKT 
phosphorylation was detectable after combined PTEN/PHLPP1 inhibition (1.9-fold 
increase, Figure 17C). These results confirmed the relevance of both phosphatases in the 
regulation of AKT. However, how the phosphatases affect AKT activation in HCC cells 
was unclear. 
Although Scrib
WT
 and Scrib
P305L
 didn't show differential binding to PHLPP1 and PTEN, 
the subcellular localizations of Scrib/PHLPP1/PTEN complexes, which is closely 
associated with the activity of both phosphatases, might vary. For example, post-
translational modifications of PTEN at its membranous-associated PDZ domain led to 
changed protein stability [73]. For this reason, the subcellular localizations of PHLPP1 
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and PTEN were compared in both cell lines stably expressing Scrib
WT
 and Scrib
P305L
 by 
western immunoblotting. Indeed, PHLPP1 and PTEN were predominately reduced in the 
membranous fractions of Scrib
P305L
-expressing cells (PTEN: 67% reduction; PHLPP1: 
62% reduction, Figure 17D). The possibility of transcriptional regulation of PHLPP1 and 
PTEN in these cells was excluded by real-time PCR (Figure 17E).  
In cells with cytoplasmic Scrib, PHLPP1 and PTEN levels were reduced especially at the 
plasma membrane, which may be associated with decreased protein stabilities. To further 
analyze the impact of cytoplasmic Scrib on PHLPP1 and PTEN stability, protein lysates 
were collected at different time points after the administration of protein synthesis 
inhibitor CHX. Indeed, both PHLPP1 and PTEN were degraded much faster in the cells 
expressing Scrib
P305L
 than Scrib
WT
. The half-life of PHLPP1 was 6 hours in Scrib
WT 
cells 
and 3.5 hours in Scrib
P305L
 cells. Similarly, the half-life of PTEN was 48 hours in Scrib
WT
 
cells and 32 hours in Scrib
P305L 
cells (Figure 17F). In order to figure out if the decreased 
phosphatase stability was due to the increased proteasomal activity, Scrib
WT
 cells and 
Scrib
P305L 
cells were treated with proteasome inhibitor MG132 to block protein 
degradation. Interestingly, both phosphatases PHLPP1 and PTEN were obviously 
increased in Scrib
P305L 
cells but not in Scrib
WT 
cells (Figure 17G). Moreover, 
immunoprecipitation analysis of PHLPP1 and PTEN detected higher amount of 
ubiquitinated PHLPP1 and PTEN in Scrib
P305L 
cells compared to Scrib
WT 
cells (Figure 
17H). 
These results revealed that the interaction between membranous and cytoplasmic Scrib 
PHLPP1 and PTEN at specific subcellular locations. In addition, cytoplasmic-localized 
Scrib
 
leads to augmented degradation of PHLPP1 and PTEN via ubiquitination, which 
eventually activates PI3K/AKT-mediated signaling.  
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Figure 17: Cytoplasmic Scrib destabilizes the phosphatases PTEN and PHLPP1. (A) Co-IP 
experiments illustrate the interactions between PHLPP1 with Scrib
WT
 and Scrib
P305L
. Scrib was 
precipitated using an antibody against GFP. (B) Co-IP experiments demonstrate the interactions 
between PTEN with Scrib
WT
 and Scrib
P305L
. For (A) and (B), equal amounts of IgG antibody were 
used as negative controls. (C) Western immunoblot of phospho-AKT after siRNA-mediated inhibition 
of PTEN and PHLPP1. Bar chart shows the normalized results from 3 independent experiments. 
Nonsense siRNA (NS) was used as a control. (D) Protein analysis of PHLPP1 and PTEN in 
membranous and cytoplasmic protein fractions. Na
+
-K
+
-ATPase and ß-tubulin served as the loading 
controls for membranous and cytoplasmic fractions respectively. (E) Real-time PCR compares the 
mRNA levels of PHLPP1 or PTEN in Scrib
WT
 and Scrib
P305L
 cells. (F) CHX protein stability assays of 
PHLPP1 and PTEN in cells expressing Scrib
P305L
.
 
Polynomial regression graphs for PHLPP1 and 
PTEN were plotted from 3 independent experiments. (G) Cells were treated with MG132 (1 μM) 
overnight before protein isolation. DMSO served as a negative control. (H) Cells were pre-treated 
with MG132 (1 μM) overnight. For PHLPP1, protein was isolated under denatured condition, and 
detected with ubiquitination antibody. For PTEN, protein was precipitated with ubiquitin and detected 
with PTEN antibody. IP: immunoprecipitation, IB: immunoblotting. 
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5.7 Identification of target genes induced by cytoplasmic Scrib 
To identify the functional relevant downstream effector mechanisms of cytoplasmic 
Scrib, transcriptome analysis of cells stably expressing of Scrib
WT
 and Scrib
P305L
 was 
performed. For each RNA sample, three biological replicates were analyzed. Genes with 
changes ≥1.6 fold or ≤0.63 fold and with adjusted P-value ≤0.05 were selected. 
According to these criteria, 81 upregulated genes and 54 downregulated genes were 
found in Scrib
P305L
 expressing cells. KEGG database was used to for the network 
enrichment analysis of gene signatures and the GeneCards database was used for the 
functional annotation of selected genes [74, 75].  
Two groups of target genes (downregulated or upregulated) were selected according to 
their differential expression in Scrib
P305L
-positive cells compared to Scrib
WT
-positive 
cells. In the group of downregulated genes (n=54), three genes were described to be the 
WNT pathway inhibitors (BICC1, DKK1 and DKK4) according to the functional 
annotation by GeneCards database (Figure 18). In the group of positively regulated genes 
(n=81), 19 genes (23%) were related to cell invasion/migration according to the 
functional annotation and relevant publications. These 19 genes play a role in epithelial-
mesenchymal transition (EMT), tumor extracellular matrix (ECM) remodeling and actin 
reorganization (Figure 19).  
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Figure 18: Genes downregulated in Scrib
P305L
 cells. The heatmap shows the 54 genes significantly 
downregulated in the cell line stably expressing cytoplasmic Scrib
P305L
 in comparison to Scrib
WT
 cells 
(P≤0.05, fold change ≤0.63). Gene expression level is depicted by the blue-red intensities (blue 
indicates reduced genes). RNA samples and genes names of potential downstream targets are listed in 
x- and y-axis respectively. ** indicates genes negatively regulating WNT signalling pathway.   
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Figure 19: Genes upregulated in Scrib
P305L
 cells. Heatmap shows 81 genes significantly upregulated 
in the cell line stably expressing cytoplasmic Scrib
P305L
 in comparison to Scrib
WT
 cells (P≤0.05, fold 
change≥1.60). Gene expression level is depicted by the blue-red intensities (red indicates upregulated 
genes). Among the 81 upregulated genes, 19 genes (indicated by *) play have been described in the 
regulating cell motility, EMT, or related to tumor ECM remodelling. 
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Considering the gene expression levels induced by cytoplasmic Scrib, as well as the 
importance of genes in cell invasion/migration, eight out of 19 genes were selected for 
further analysis. For example, increased N-cadherin levels may affect cell-cell junctions 
and the induction of cell invasiveness [76]. Both carcinoembryonic antigen-related cell 
adhesion molecule 1 (CEACAM1) and melanoma cell adhesion molecule (MCAM) are 
cell adhesion molecules, which are known inducers of EMT and tumor invasiveness [77]. 
Fascin 1 has important function in the bundling of actin filament, which induces the 
filamentous actin (F-actin) in invading cells [78]. Secreted protein acidic and cysteine 
rich (SPARC, synonym: Osteonectin), TIMP metallopeptidase inhibitor 1 (TIMP1), 
TIMP metallopeptidase inhibitor 2 (TIMP2) and S100 calcium binding protein A10 
(S100A10) are secreted factors that play roles in the remodeling of tumor ECM [79-81]. 
Real-time PCR were carried out to confirm the overexpression of these invasion-
associated genes in Scrib
P305L 
and Scrib
WT
 cells. As expected, all the selected genes were 
significantly elevated in the Scrib
P305L
 cells compared to Scrib
WT 
cells with SPARC 
showing the highest induction (133-fold increase, Figure 20A). To confirm increased 
SPARC secretion in Scrib
P305L
 cells, a SPARC ELISA assay was used. The SPARC 
protein levels were 6.5-fold higher in cultured medium of Scrib
P305L
 positive cells (15 
ng/ml), compared to Scrib
WT
 positive cells (2 ng/ml) (Figure 20C). In addition, the 
overexpression of N-cadherin, CEACAM1 and Fascin 1 at protein levels were confirmed 
by western immunoblotting (Figure 20B). 
Because it is known that the upregulation of N-cadherin is often accompanied by the 
downregulation of E-cadherin in the process of EMT in epithelial cells [76], I tested the 
localization of both cadherins by immunofluorescence. In Scrib
WT
 expressing cells, E-
cadherin was clearly localized near the plasma membrane, while in the Scrib
P305L 
cells, E-
cadherin predominantly showed a cytoplasmic localization. On the other hand, the 
Scrib
P305L
 expressing cells showed a strong membranous stain for N-cadherin, which was 
much weaker in the Scrib
WT 
cells (Figure 20D). These data demonstrate that cytoplasmic 
Scrib induces an EMT-like phenotype partly via the regulation of cadherin adhesion 
molecules.  
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Because SPARC showed the strongest induction on mRNA and protein levels in cells 
expressing cytoplasmic Scrib
P305L
, this factor was chosen for further analyses. SPARC 
has been shown to mediate the interaction of cell surface molecules and extracellular 
collagen fibers, leading to the  induction of tumor cell invasion in the surrounding ECM 
[82]. For this reason, invasion assays with recombinant SPARC protein were performed 
to confirm the regulatory effect of SPARC. As previously demonstrated, Scrib
WT
-
expressing cells with low-SPARC levels showed a low invasive capacity (Figure 14D). 
Administration of recombinant SPARC significantly induced the invasiveness of Scrib
WT
 
expressing cells (Figure 20E). In addition, the invasive capacity of Scrib
P305L
 expressing 
cells, which have a high basal invasion potential, was suppressed when SPARC 
expression was inhibited by the siRNA (Figure 20F). 
Taken together, these results demonstrate that overexpression of cytoplasmic Scrib 
induces tumor invasiveness via the upregulation of genes, including SPARC, which are 
involved in EMT and ECM remodelling.   
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Figure 20: Cytoplasmic Scrib induces HCC cell invasiveness. (A) Real-time PCR analysis confirms 
the overexpression of the eight selected genes, which are involved in EMT and cell migration (N-
cadherin, CEACAM1, Fascin1, SPARC, TIMP1, TIMP2, and S100A10). Mann-Whitney U test was 
performed (P≤0.01). (B) Western immunoblot analysis confirms increased amounts of N-cadherin, 
CEACAM1 and Fascin 1 in the cells expressing Scrib
P305L
. (C) Human SPARC Quantikine ELISA 
assay was used to detect SPARC in the supernatant of cultured Scrib
P305L
 expressing cells in 
comparison to Scrib
WT
 expressing cells. Supernatant was collected from stable cell lines under 
starvation condition after 12 hours. (D) Immunofluorescence stains of N-cadherin and E-cadherin 
illustrates the overexpression of N-cadherin and the cytoplasmic localization of E-cadherin in 
Scrib
P305L
 cells. Magnification: 400-fold. Scale bars: 40 μm. (E) Cell Invasion was measured 96 hours 
after SPARC stimulation. Cells were stained with crystal violet (blue color). (F) Invasion assays 
illustrate the SPARC-induced cell invasion was abolished after siRNA-mediated silencing of SPARC 
in Scrib
P305L
 cells. The outer wells were supplemented with full FCS. Invasion was measured 72 hours 
after transfection. For (E) and (F), photos were taken under 100-fold magnification, scale bars: 200 
µm. Invading cells were counted in seven different visual fields under 40-fold magnification. 
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5.8 The role of AP1 family in regulating cytoplasmic Scrib-target 
genes 
AP1 transcriptional factors are activated by extracellular stimuli and stress, such as 
cytokines and growth factors. It can be activated by a variety of intracellular signaling 
pathways, e.g., JNK, ERK，p38 and AKT [83]. In order to define the transcriptional 
factor, which accounts for the upregulation of Scrib-target genes via AKT, the AP1 
family constituents (c-Jun, ATF2 and JunB) were compared in nuclear fractions of cells 
stably expressing Scrib
WT
 or Scrib
P305L
. Both increased total and phosphorylated protein 
levels of c-Jun and JunB were observed, while induced phosphorylated level without 
changing the total amount of ATF2 was detected in the cells expressing Scrib
P305L
 (Figure 
21A). To test if Scrib affects the transcription of AP1 family constituents, real-time PCR 
was performed to compare c-Jun, ATF2, and JunB mRNA levels. Interestingly, c-Jun was 
transcriptional upregulated in Scrib
P305L 
expressing
 
cells, while ATF2 and JunB were not 
affected (Figure 21B).   
In the next step, I evaluated the regulatory effect of these AP1 family members on 
cytoplasmic Scrib-target genes by siRNA-mediated gene silencing in Scrib
P305L
 
expressing cells. After c-Jun silencing, S100A10 was repressed, however, the other 
potential target genes were not drastically regulated at all or slightly induced (Figure 
21C). After ATF2 inhibition, SPARC, TIMP2 and MCAM were reduced, while Jun-B 
silencing led to diminished SPARC, TIMP1, TIMP2, CEACAM, S100A10 and MCAM 
transcript levels (Figure 21D/E). Especially, the impact of ATF2 and Jun-B on SPARC 
protein secretion in cells stably expressing Scrib
P305L
 was confirmed using the SPARC 
ELISA assay (Figure 21F).  
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Figure 21: Scrib target genes are regulated by transcription factor AP1 subunits. (A) Western 
immunoblotting shows the differences of total and phosphorylated c-Jun, JunB and ATF2 in the 
nuclear fraction of Scrib
P305L
 expressing cells in comparison to Scrib
WT
 expressing cells. (B) Real-time 
PCR reveals an upregulation of c-Jun at the mRNA level in cells stably expressing Scrib
P305L
 in 
comparison to cells stably expressing Scrib
WT
. No differences were detected for ATF2 or JunB. (C) 
Real-time PCR analysis after c-Jun inhibition in Scrib
P305L 
expressing cells. Significantly regulated 
genes were S100A10 (-63%) and TIMP2 (-24%). (D) Real-time PCR of Scrib
P305L
 expressing cells 
after ATF2 silencing. Significantly regulated genes were: SPARC (-73%), TIMP2 (-39%) and MCAM 
(-33%). (E) Real-time PCR analysis after JunB inhibition in Scrib
P305L 
expressing cells. Significantly 
regulated genes were SPARC (-26%), TIMP1 (-38%), TIMP2 (-38%), CEACAM1 (-55%), S100A10 
(-49%) and MCAM (-50%). (F) SPARC ELISA assay confirms reduced secretion of SPARC after 
ATF2 (-66%) or JunB (-29%) silencing. The siRNA treatment was performed under full FCS 
condition. Supernatant were collected from cells after starvation for 12 hours. SPARC concentrations 
in Scrib
P305L
 and Scrib
WT 
cells were determined using the SPARC Quantikine ELISA assay (3 
independent repetitions). For (C), (D), (E) and (F), UTC: untreated cells, NS: nonsense siRNA 
control. Statistical test: Mann-Whitney-U test. 
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To test if the AP1 subunits regulate SPARC expression through direct promoter binding, 
ChIP analyses were carried out in cell lines stably expressing Scrib
WT 
and Scrib
P305L
 
lines. Two different potential AP1 binding sites were predicted by the JASPAR database 
(Figure 22A). The first site was located upstream of the transcriptional start (position -
469 to -360). The second one was located within the second exon of SPARC (position 
+1890 to +1998) [84]. Primers were designed to detect these two potential binding sites, 
while primers that recognize an unspecific sequence downstream of the SPARC gene 
were designed as negative control (position +16083 to +16191). The c-Jun ChIP analysis 
revealed binding of c-Jun at the second binding site of the SPARC gene in the Scrib
P305L
 
expressing cells (Figure 22B). The ATF2 ChIP analysis demonstrated binding between 
ATF2 with both potential binding sites in the SPARC gene (Figure 22C). Similar to c-
Jun, binding of JunB was detectable at the second binding site in the SPARC gene 
(Figure 22D). Importantly, none of these interactions between AP1 family members and 
the SPARC promoter were found in Scrib
WT
 expressing cells (Figure 22B-D).  
Together, these data suggest that cytoplasmic Scrib induces invasion-associated genes via 
activation of the AP1 transcriptional factors ATF2 and JunB. Interestingly, c-Jun also 
binds to the SPARC promoter. However, this AP1 family member negatively regulates 
SPARC expression. 
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Figure 22: Interaction of the AP1 family member c-Jun, ATF2 and JunB with the SPARC 
promoter. (A) Scheme of two AP1 binding sites in the human SPARC gene promoter region. Primers 
used for ChIP analysis are indicated with grey arrows. (B) Real-time PCR for c-Jun ChIP analysis in 
cells stably expressing Scrib
WT
 and Scrib
P305L
. (C) Real-time PCR for ATF2 ChIP analysis in cells 
stably expressing Scrib
WT
 and Scrib
P305L
.  (D) Real-time PCR for JunB ChIP analysis in cells stably 
expressing Scrib
WT
 and Scrib
P305L
. For (B), (C) and (D), the amount of precipitated DNA was 
normalized to a standard curve of genomic DNA. Statistical test: Mann-Whitney-U test. 
 
5.9 Cytoplasmic Scrib promotes c-MYC-induced tumor 
formation 
Previous studies illustrated that cytoplasmic Scrib also facilitates oncogenic properties 
[42]. For this reason, mouse experiments were carried out to define the oncogenic 
potential of cytoplasmic Scrib
P305L
 in comparison to Scrib
WT 
after their stable genomic 
integration in non-malignant hepatocytes in vivo by using HDTV injection. For this, 
human Scrib
WT
 and Scrib
P305L
 were cloned into pT3-EF1α vectors, which allowed the 
integration of genes in hepatocytes after co-expression of the transposase SB in mice 
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(HDTV injection gene delivery technique). Two ml of plasmids diluted in PBS were 
injected into lateral tail-vein of each mouse in 7-10 seconds. Increased pressure in liver 
vessels forced the entry of plasmids through highly permeable capillary endothelium into 
injured hepatocyte [64, 85].  
We hypothesized that c-MYC overexpression might be necessary for Scrib to gain its full 
oncogenic properties, because c-MYC is frequently co-amplified with Scrib at the 
chromosome 8q.24 [86].  For this reason, the pT3-EF1α-c-MYC vector was co-injected 
with pT3-EF1α-hScribWT-GFP or pT3-EF1α-hScribP305L-GFP vectors. An IRES sequence 
in the pT3-EF1α-hScribWT-GFP and pT3-EF1α-hScribP305L constructs allowed the co-
expression of GFP and Scrib isoforms without the formation of fusion proteins. For this 
reason, GFP expression was used as a reporter to determine the transfection and 
integration efficiency of exogenous Scrib.  
Four weeks after injection, macroscopically visible tumors formed in the majority of the 
mice that expressing c-MYC and hScrib
P305L
, whereas small and microscopically visible 
lesions were found in the mice that received c-MYC alone or c-MYC/hScrib
WT
 (Figure 
23A). Increased levels of tested EMT and cell invasive signatures (SPARC, CDH2, 
TIMP2), and an activation of AKT was observed in samples with c-MYC/Scrib
P305L
 co-
expression was observed in comparison to c-MYC/Scrib
WT 
samples (Figure 23B/C). 
Notably, immunohistochemical analysis revealed a prominent induction of AKT and 
ATF2 phosphorylation as well as SPARC production in the tumors induced by c-
MYC/Scrib
P305L
 but not in control tumors (Figure 5D). Together these results indicate 
that cytoplasmic Scrib selectively activates AKT in hepatocytes and supports liver tumor 
formation in conjunction with another oncogene in vivo. 
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Figure 23: Cytoplasmic Scrib induces tumor formation after hydrodynamic gene delivery.  (A) 
Eight-weeks old FVB mice were injected with vectors coding for c-MYC, SB and one of IRES-GFP 
(pT3-EF1α-hScrib
WT
-GFP, pT3-EF1α-hScrib
P305L
-GFP or pT3-EF1α-GFP empty vectors). Mouse 
livers were collected 4 weeks after injection. Scale bar: 1 cm. (B) Scrib target gene expressions were 
compared in liver tissues isolated from the mice injected with Scrib
WT
/c-MYC (n=4) or Scrib
P305L
/c-
MYC (n=4). Statistic test: Mann-Whitney U. (C) Western immunoblot analysis revealed increased 
amounts of phospho-AKT in mouse livers injected with Scrib
WT
/c-MYC compared to the mouse livers 
injected with Scrib
P305L
/c-MYC. The presence of GFP protein confirmed the stable integration of 
Scrib-transgenes in mouse livers. (D) HE overviews and immunohistochemical analysis of pAKT, 
pATF2 and SPARC in Scrib
P305L
/c-MYC- or c-MYC- induced liver tumor. Scrib
WT
/c-MYC co-
injection induced one single microscopically visible tumor, which was not suitable for histological 
analysis. Tumor and surrounding healthy tissues are shown. N: normal liver, T: tumor. Photos were 
taken under 200x magnification, scale bar: 50 μm. Dash lines indicate the hepatocyte-tumor border.  
 
 
 
 
RESULTS 
 
83 
 
5.10 Cytoplasmic Scrib, AKT and ATF2 are associated with HCC 
prognosis 
To confirm the previous findings in HCC patients, IHC stains of Scrib, phospho-AKT, E-
cadherin and phospho-ATF2 were carried out using a HCC TMA containing human 
HCCs and histologically normal livers (7 histologically normal livers, 105 HCCs). 
Immunohistochemistry stains were scored by multiplying quantitative and qualitative 
parameters (see Chapter 4.8.2).  In the non-tumor livers and well-differentiated HCCs, 
Scrib showed predominantly a membranous localization (Figure 24A). In contrast, in 
poorly differentiated HCC tissues, Scrib was frequently located in the cytoplasm (Figure 
24A). Because the function of Scrib depends on its localization, both membranous and 
cytoplasmic Scrib were evaluated using individual scores. Phospho-AKT was 
predominantly expressed in the cytoplasm of poorly differentiated HCCs, while it was 
not detestable in non-tumor livers and well-differentiated HCCs. More importantly, the 
expression of cytoplasmic Scrib positively correlated with the expression of phospho-
AKT (rs=0.54, p≤0.001). Phospho-ATF2 was expressed in the nuclei of HCCs, which 
also had a positive correlation with cytoplasmic Scrib expression (rs=0.28, p=0.037). In 
addition, E-cadherin was expressed on the plasma membrane of non-tumor livers and 
well-differentiated HCCs, which is frequently lost during the process of EMT in tumor 
development. Interestingly, the cytoplasmic Scrib expression negatively correlated with 
the membranous expression of E-cadherin (rs=-0.49, p≤0.001) (Figure 24A).  
To figure out if the IHC stains of TMAs (Scrib, phospho-AKT, phospho-ATF2 and E-
cadherin) were statistically associated with tumor de-differentiation, IHC scores for the 
respective proteins were compared with HCC grading (Figure 24B). Cytoplasmic Scrib 
stains correlated with a poorer tumor differentiation (rs=0.24, p=0.02), whereas 
membranous E-cadherin stains correlated with a better tumor differentiation (rs=-0.21, 
p=0.04). Phospho-AKT expression also showed association with tumor de-
differentiation, nevertheless this association did not reach the significance level (p=0.1).   
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Figure 24: Cytoplasmic Scrib correlates with AKT and ATF2 activity in human HCC tissues. 
(A) Representative IHC stains illustrates the association of cytoplasmic Scrib with an EMT-like 
phenotype (loss of E-cadherin) and AKT pathway activation (phospho-AKT; pAKT). Exemplary IHC 
stains of one non-tumorous liver, two HCC tissues with strong cytoplasmic Scrib, and two HCC 
tissues with predominantly membranous Scrib are shown. Photos were taken under 400-fold 
magnification (scale bars: 50 µm) and 80-fold magnification (scale bars: 200 µm). (B) Proportional 
bar charts illustrate the correlation of IHC stains with tumor de-differentiation. IHC scores (0-12) were 
used for the correlation with the tumor grading (0: normal liver tissue, 1: G1, 2: G2. 3: G3, 4: G4). 
Spearman’s correlation was used for statistical testing. Constituents of each scoring range (high score, 
medium sore and low score) are indicated with different grayscales. 
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The previous results strongly indicated that gene signatures induced by cytoplasmic Scrib 
could be used for the identification of HCC patients, who may have a higher risk to 
develop tumor metastasis.  Therefore, I next aimed to correlate the gene signature 
induced by cytoplasmic Scrib with HCC patient prognosis. For this, a HCC cohort 
containing 91 patients with defined prognostic subgroups was applied (Figure 25). In this 
HCC cohort, transcriptome expression data of patients with good or poor clinical 
outcome was analyzed for the presence of gene induced by cytoplasmic Scrib [87]. Genes 
identified previously as Scrib-target genes (upregulated or downregulated) in the 
Scrib
P305L
 cells were employed for Gene set enrichment analysis (GSEA). Interestingly, 
the GSEA revealed a significant correlation between the Scrib
P305L
-induced gene 
signature (n=65) and poorer patient prognosis. Furthermore, invasion-associated genes 
(n=16) were selected from the upregulated genes, which again showed a significant 
enrichment in HCC patients with poor prognosis (Figure 25 A, B). Vice versa, genes that 
were downregulated by Scrib
P305L
 (n=46) showed a significant association with better 
HCC prognosis (Figure 25C).  
Lastly, survival data from a 249 patients HCC cohort were further used for the analysis of 
the eight selected Scrib-target genes SPARC, CDH2, FSCN1, CEACAM1, TIMP1, 
TIMP2, S100A10 and MCAM [65]. For SPARC, CDH2, TIMP2, S100A10 and MCAM, 
significant induction in HCC tissues compared to the corresponding normal livers were 
detectable (Figure 26A). Moreover, the overexpression of CDH2 and MCAM in HCC 
tissues positively correlated with poorer overall and recurrence-free survivals (Figure 
26B). When patient data were compared with the gene expression of SPARC, CDH2, 
S100A10 and TIMP2 in surrounding tissues, all Scrib
P305L
 target genes exhibited 
significant correlations with worse overall survival recurrence-free survivals (Figure 27). 
To sum up, these data confirmed the association between the overexpression of 
cytoplasmic Scrib with the activation of AKT and ATF2 in HCC tissues. The 
overexpression of Scrib-target genes is associated with poorer prognosis in HCC patients. 
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Figure 25: Expression of Scrib target genes correlates with HCC prognosis. (A) GSEA and 
respective heatmap of Scrib-induced target genes in the pre-defined subgroups of HCC patients with 
poor or better prognosis. (B) GSEA and heatmap of invasion-associated genes selected from Scrib-
upregulated signatures in the pre-defined two subgroups. (C) GSEA and heatmap of Scrib-
downregulated signatures in both HCC subgroups. The GSEA was performed using GSEA software 
provided by the Broad Institute [88]. For A-C, normalized enrichment score (NES) was used to reﬂect 
the enrichment of signatures for each group. Statistical signiﬁcance was calculated by nominal P-value 
using an empirical phenotype-based permutation test. Heatmaps show the expression of Scrib-target 
genes in the two subgroups of HCC patients with poorer or better prognosis.  
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Figure 26: Overexpression of Scrib-target genes in HCC tissues. (A)  Gene transcriptome analyses 
reveal that SPARC, CDH2, TIMP2, S100A10 and MCAM are significantly overexpressed in HCC 
tissues compared to surrounding livers. (B) Kaplan-Meier curves illustrate that higher expression of 
CDH2 (Log2 expression≥8.4) and MCAM (Log2 expression≥5.3) levels correlate with poorer overall 
and recurrence-free survivals. The overexpression of SPARC in the HCC tissues does not significantly 
correlate with survivals. Log-Rank test was used for the survival analyses. 
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Figure 27: Overexpression of Scrib-target genes in tumor-surrounding tissues correlate with 
poorer survivals. Kaplan-Meier curves shows higher expression of SPARC (Log2 expression≥8.7 for 
overall survival, Log2 expression≥7.7 for recurrence-free survival), CDH2 (Log2 expression≥7.9), 
S100A10 (Log2 expression≥9.0) and TIMP2 (Log2 expression≥5.7 for overall survival, Log2 
expression≥5.4 for recurrence-free survival) mRNA levels in the tumor-surrounding tissues positively 
correlate with both worse overall and recurrence-free survivals. Log-Rank test was used for the 
survival analyses. 
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6. DISCUSSION 
 
6.1 Dysregulation of cell polarity proteins defines HCC patients with 
poor clinical outcome  
Previous studies already identified alterations of cell polarity genes in different solid cancer cell 
types. These alterations include the downregulation of polarity proteins (e.g. Dlg, Lgl and PATJ), 
their overexpression (e.g. Par6, aPKC) or mislocalization (e.g. Par3, Scrib, aPKC) [33]. However, 
a systematic study of EPP components and their impact on the development and progression of 
HCC was missing, so far. In this study, 33 different polarity genes, which belong to the apical 
Crumbs complex, the subapical Par complex, and the basolateral Scrib complex were compared 
according to the expression levels in HCCs and surrounding tissues [65]. The comparison of 
transcript levels in HCCs with clinical data revealed candidate polarity genes, which may act as 
oncogenes (in case of overexpression) or tumor-suppressor genes (in case of downregulation). 
Although this transcriptome analysis allowed the identification of dysregulated factors; it cannot 
identify genes carrying mutations (e.g. point-mutations or small deletions) with direct impact on 
protein functionality.  
In the subgroup of overexpressed polarity genes that were associated with oncogenic properties, 
Scrib, CDC42, CTNNA1 and DLG5 were identified. Their overexpression in HCCs was 
associated with poor patient outcome. Notably, two of these polarity genes belong to the 
basolateral Scrib complex (Scrib and DLG5), indicating the importance of this complex in 
hepatocarcinogenesis. In addition, CTNNA1 (coding for α–catenin) also shows a close spatial 
proximity with the Scrib complex at the AJs [89]. A previous study demonstrated the activation 
of Wnt singling pathway in HCC patients with multiple intrahepatic metastasis, which was 
associated with β-catenin mutations in 70-100% [16]. Although little is known about α–catenin in 
HCC development, it has been suggested that this protein supports tumorigenesis via the 
interaction with β-catenin and the actin cytoskeleton [90]. The GTPase CDC42, which plays an 
important role in the dynamic reorganization of actin filament in migrating cells [39], was 
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overexpressed and associated with a poor HCC prognosis in our study. The oncogenic property of 
CDC42 identified in my study is in agreement with a previous study, which demonstrated the 
important role of CDC42 and other Rho GTPases in HCC invasion and migration [91]. 
In the subgroup of reduced polarity genes with potential tumor suppressive effects, CDH1 
(coding for E-cadherin), LLGL1, TJP1, LIN7C, and MPP5 were identified. Their presence 
correlated with a better HCC outcome. Among these polarity genes, E-cadherin has been widely 
accepted as a tumor-suppressor in HCC, which is downregulated in a subgroup of HCC patients, 
and is associated with Wnt pathway activation in intrahepatic metastasis [16, 92]. Like E-
cadherin, TJP1 is a major component of TJs. In HCC, loss of TJs and associated proteins (e.g. 
ZO-1 and claudin) have been connected with the tumor cell dedifferentiation and early metastasis 
[93]. Two other regulated factors, LIN7C and MPP5, belong to the apical Crumbs complex in 
association with TJs [32]. Although little is known about the role of LIN7C and MPP5 
(synonyms: PALS1) in cancer development, these two polarity proteins form a complex with the 
apical localized membrane protein Angiomotin, which can inhibit mouse liver tumor formation 
via the Hippo/YAP signaling pathway [49, 94].  
This systematic analysis of polarity genes in HCC patient material suggested the tumor-
promoting role of the basolateral Scrib complex and the tumor-suppressing property of the apical 
Crumbs complex. In many cases, the causes for the enrichment of polarity proteins from the same 
complexes sharing a specific biological functionality (oncogenic or tumor-suppressive) remain 
unknown. One explanation could be that individual polarity complexes may preferentially 
modulate specific intracellular signaling pathways, which may affect different aspects of tumor 
cell biology [33].  
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6.2 The Scrib gene is frequently amplified and Scrib protein is enriched 
in the cytoplasm of HCC cells 
Based on stringent selection criteria (significant overexpression and association with patient 
outcome), Scrib was further analyzed for its relevance in liver cancer. My study illustrated that 
Scrib overexpression in HCCs compared to normal livers was associated with poor clinical 
outcome. The upregulation of Scrib was also detected in other human tumor entities (e.g. breast 
cancer and lung adenocarcinoma), which confirmed the importance of Scrib in different cancer 
types [95]. Interestingly, the Scrib gene is located on chromosome 8q.24.3, which is frequently 
amplified in many cancer types [96, 97]. To define the cause for Scrib upregulation, Scrib 
expression levels in HCC samples with 8q24.3 gains were compared with samples without 
detectable genomic alterations. Indeed, transcriptional upregulation of Scrib was associated with 
chromosome amplifications at 8q24.3 (see Chapter 5.1). A meta-analysis of comparative genomic 
hybridization data derived from 785 HCC patients confirmed that the Scrib gene locus was 
amplified in more than 40% of all HCC patients [98]. Together with my study, these illustrate 
that the Scrib upregulation in HCC patients is probably due to the genomic amplification. 
Analysis of Scrib localization in HCC tissues and healthy livers revealed the membranous loss 
and cytoplasmic enrichment of Scrib in the majority of HCC patients, suggesting the loss of 
membranous Scrib expression is one important step during liver cancer formation. Other studies 
have equally observed the association between cancer development and cytoplasmic Scrib 
localization. For example, disassembly of the Scrib complex led to ovarian tumor formation in 
Drosophila melanogaster [99], while overexpression of cytoplasmic Scrib induced hyperplastic 
nodules in mouse mammary glands [42]. A recent study showed Scrib was localized in the 
cytoplasm in all analyzed HCC tissues (n=6), whereas it was mostly membranous localized in 
healthy liver (3/4) [100]. These data further support that the oncogenic function of Scrib is 
strictly dependent on its subcellular localization.  
Previous studies have identified the membranous localization of Scrib in cells depends on its 
LRR and PDZ domains [101], and mutations in these two domains led to cytoplasmic 
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mislocalization of Scrib and disturbance of epithelial polarity in Drosophila melanogaster 
embryos and breast cancer cells [42, 102]. By analyzing exome sequencing data derived from the 
TCGA database, two missense mutations within the LRR or PDZ domains were identified in 
HCC patients (n=366). These mutations represent amino acid changes (R220W and A799V), 
which are present in 2% of HCC patients [103]. Thus, mutations in LRR and PDZ domains can 
be one explanation for the cytoplasmic localization of Scrib. However, the frequency of HCC 
patients carrying Scrib mutations is much lower than the HCC patients with cytoplasmic-
localized Scrib (2% vs. 69%), which illustrates that other mechanism may affect the subcellular 
Scrib localization in HCC cells.  
Underlying liver diseases such as liver fibrosis and cirrhosis may represent one reason for the 
cytoplasmic enrichment of Scrib in hepatocytes. During this pathological process, changes in the 
composition of ECM due to elevated production of collagen and reorganization of cell polarity 
modules is detectable [19], which might affect the release of cell polarity proteins from their 
complexes. Another possible reason for Scrib mislocalization might be infection with is hepatitis 
virus. So far, only the TJ-associated protein Claudin-1 has been described to interact with HCV-
derived proteins, which induces HCC invasiveness via ERK signaling pathway [104]. Scrib 
stability has been connected with human papillomavirus (HPV) infection, which induces 
ubiquitination and degradation of the Scrib complex [105]. However, if the infection with 
hepatitis viruses is a cause for the observed cytoplasmic Scrib enrichment is not clear, yet. For 
example, the analyzed HCC cohort consisted of HBV-positive cancer patients [65], however, 
only a subgroup of patients showed a clear Scrib alteration. In addition, a recent study revealed 
that palmitoylation of Scrib was necessary for its membranous localization [106], however, if this 
secondary modification is also involved in the observed mislocalization in HCC cells has not 
been analyzed, so far.  
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6.3 Cytoplasmic Scrib activates AKT signaling pathway via the 
destabilization of PHLPP1/PTEN 
Because one previous study identified TAZ as the downstream effector of Scrib in breast cancer 
cells [50], similar effects were expected for HCC cells. However, neither was the TAZ paralogue 
YAP differentially phosphorylated in the Scrib
WT
 and Scrib
P305L
-expression cells, nor did 
YAP/TAZ translocate into the nucleus via siRNA-mediated Scrib inhibition (see Figure 15A/B), 
which suggested that Scrib may regulate different signaling pathways in a cell type-dependent 
manner. Other tumor-associated signaling pathways, including ERK1/2, JNK, AKT and p38 
pathways were also not significantly affected by cytoplasmic Scrib. Instead, the AKT pathway 
was identified as the central downstream effector according to the used experimental setup 
(Figure 15C). This result is in agreement with a study in breast cancer, in which overexpression 
of Scrib
P305L
 induced AKT-mTOR activity in cancer cells [42]. However, another breast cancer 
study and a recent study in HCC identified the ERK1/2 as a downstream effector of Scrib [71, 
100]. In these two studies, the ERK1/2 was dephosphorylated when Scrib
WT 
was overexpressed 
in cancer cells, although these two studies had different observations regarding the upstream 
activities of ERK1/2 regulators: rapidly accelerated fibrosarcoma (RAF) and mitogen-activated 
protein kinase kinase (MEK) [71, 100]. Taken into account a very early study in Drosophila 
melanogaster, which identified an enhanced tumor growth after rat sarcoma (Ras) and Scrib 
alterations [107], it is possible that both PI3K-AKT and Ras-ERK pathways cooperate with 
cytoplasmic Scrib during  tumor development. Because PI3K-AKT and Ras-ERK intensively 
cross-talks with each other, e.g. phosphatidyl-inositol,3,4,5-triphosphate (PIP3) is activated by 
Ras [108], it is not clear if the differential activation of the two pathways is mediated through 
independent molecular mechanism. Because PI3K-AKT and Ras-ERK have a common 
downstream effector (S6 protein) [108], it is possible that similar target genes and biological 
processes can be induced by cytoplasmic Scrib via activation of AKT or ERK signaling.   
The phosphatases PHLPP1 and PTEN were analyzed as potential upstream regulators of AKT 
because they have previously been connected with Scrib in two independent studies [109, 110]. 
PTEN is a negative regulator of PI3K/AKT, which dephosphorylates PIP3 and therefore blocks 
the recruitment and phosphorylation of AKT at cell membrane [111]. Different from PTEN, 
PHLPP1 directly dephosphorylates AKT (on Ser473) and protein kinase C (PKC), and both 
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modifications inhibit the activation of AKT and its downstream effectors [109]. In my thesis, I 
describe the interaction of the two important AKT phosphatases (PTEN and PHLPP1) with 
membranous and cytoplasmic localized Scrib. Membranous Scrib stabilized PTEN and PHLPP1 
at the plasma membrane, while cytoplasmic Scrib induced the rapid proteasomal degradation of 
phosphatases. These results were confirmed by studies in breast cancer cells demonstrating 
binding capacities of Scrib with both phosphatases [42, 72]. However, my data further suggests 
how cytoplasmic Scrib leads to AKT activation. Here, PTEN and PHLPP1, which are tethered to 
cytoplasmic Scrib, are quickly degraded by ubiquitination, and thus AKT and downstream 
pathway are constitutively activated (Figure 17).  
 
Figure 28: Cytoplasmic Scrib activates AKT signaling via the destabilization of PHLPP1 and PTEN. (A)  
Under physiological conditions, Scrib co-localizes with the AJ of the plasma membrane. It binds to the 
PI3K/AKT phosphatases: PHLPP1 and PTEN. PTEN dephosphorylates PIP3 to PIP2, antagonizing the effect 
of PI3K, while PHLPP1 directly dephosphorylates AKT [109]. AKT and the downstream pathway are 
negatively regulated by PHLPP1 and PTEN [109]. (B) In HCC cells, Scrib is enriched in the cytoplasm, which 
leads to a disassembly of the Scrib/PHLPP1/PTEN complex and degradation of the phosphatases. As a 
consequence, PI3K constantly phosphorylates PIP2 to PIP3, which allows the phosphorylation of AKT by 
pyruvate dehydrogenase kinase (PDK) [111]. RTK - receptor tyrosine kinases. 
 
DISCUSSION 
 
95 
 
6.4 Cytoplasmic Scrib induces a signature associated with invasiveness 
in HCC 
Functional analyses in the cell lines expressing Scrib
WT
 and Scrib
P305L
 revealed a moderate 
induction of proliferation and suppression of apoptosis. More strikingly, a strong induction of the 
cell invasive capacity was detected after cytoplasmic Scrib overexpression (Figure 14). In 
addition, transcriptome analysis of Scrib
WT
 and Scrib
P305L
 expressing cells revealed the 
dysregulation of invasion-associated genes in cells with cytoplasmic Scrib. These genes include 
cell surface adhesion molecules (N-cadherin, CEACAM1, and MCAM), an actin bundle 
component (Fascin1) and secreted factors (SPARC, TIMP1/2 and S100A10). Among these 
genes, upregulation of N-cadherin counteracts E-cadherin, which is defined as a so-called 
"cadherin switch" in the progression of EMT [76]. Another example for a Scrib
P305L
-induced and 
pro-invasive gene is Fascin. This actin binding protein facilitates the dynamic reorganization of 
actin filament at the protruding filopodia, which is found at the leading edge of migrating cells 
[112]. Fascin was previously found as a target of the EMT-associated transcriptional factor Zinc 
finger protein SNAI2, which promoted tumor growth in K-Ras overexpressed mice, and was 
associated with early metastasis in pancreatic cancer patients [113]. Among the other identified 
and Scrib
P305L
-induced genes with pro-invasive capacity TIMP1 and TIMP2, which can regulate 
the tumor microenvironment via the interaction with matrix metalloproteinases (MMPs), were 
found [114].  
Previous studies discussed the tumor-supporting impact of Scrib in cancer development in the 
context of tumor cell proliferation, cell apoptosis as well as EMT [71, 115-117]. For example, 
loss of Scrib was found to induce cell proliferation via the induction of G1 to S phase cell cycle 
transition [116, 117]. Regarding cell invasiveness, which was the most promising aspect from my 
analysis; previous studies have focused on the role of membranous Scrib in inhibiting tumor cell 
invasion and EMT [117, 118]. Loss of Scrib induced a highly invasive tumor phenotype in 
Drosophila melanogaster in combination with Ras overexpression [115]. It has also been 
illustrated that this effect of membranous Scrib was dependent on its interaction with βPIX, 
which is a GEF protein specifically activating CDC42 and RAC1 [118, 119]. However, a 
different mechanism was described in breast cancer through the negative regulation on ERK 
pathway and Zinc finger E-box binding homeobox (ZEB) transcriptional factors [71]. These 
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studies suggest that membranous-localized Scrib may inhibit EMT/cell invasion, while my results 
further demonstrate that cytoplasmic-localized Scrib may promote these invasiveness via the 
activation of genes involved in EMT, actin reorganization and ECM remodeling. In addition, the 
secreted factors (SPARC, TIMP2 and S100A10), which were upregulated by cytoplasmic Scrib, 
were associated with worse clinical outcome of HCC patients (Figure 27).  
 
6.5 SPARC in liver microenvironment induces HCC invasiveness 
SPARC was identified as one of the most interesting target gene induced by cytoplasmic Scrib. 
Functional analysis of HCC cell lines under different culture conditions with various SPARC 
levels demonstrated the indispensable role of this factor in inducing HCC cell invasiveness.   
SPARC has important functions in the formation of collagen fibrils (I and IV) and mediating the 
interaction between cells and ECM [120]. Depletion of SPARC in mice caused reduced 
expression and stability of collagen fibers [121]. For this reason, SPARC-knockout led to 
embryonic lethality in Drosophila melanogaster due to the incomplete formation of basal lamina 
[122]. However, SPARC is also important in tumor development, especially in promoting 
migration and metastasis. Mice lacking SPARC showed increased resistant to skin papillomas 
under the UV exposure [123], while SPARC-knockout mice had reduced lung metastasis 
compared to the mice with normal SPARC expression in a breast cancer xenograft mouse model 
[81].  
Difference studies identified multiple mechanisms explaining how SPARC can increase tumor 
cell invasion/metastasis and changes in ECM composition. These mechanisms include changes in 
the EMT process, enhanced integrin adhesion, and ECM remodeling [124-126]. SPARC was 
identified to activate the EMT-associated transcription factor SNAI2 in melanoma cells [124], 
and to decrease cell adhesion by reorganizing integrin subunits important for ovarian tumor cell 
invasion/metastasis [127]. Another study detected the interaction of SPARC with vascular cell 
adhesion molecule 1 (VCAM) on vascular endothelial cells, which increased vascular 
permeability via activation of the p38 pathway, and promoted melanoma metastasis in a 
xenograft mouse model [125]. Nevertheless, there are contradicting results about the role of 
SPARC in tumor development. For example, SPARC inhibited tumor cell proliferation and 
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induced cell cycle arrest via the TGF-β/Smad pathway in lung epithelial cells [128], and 
suppressed the activation of AKT pathway in ovarian cancer cells [127]. Thus, the potential 
tumor-supporting role of SPARC must be evaluated for each individual tumor entity under a 
certain pathological process.  
In case of HCC, previous findings support our results that SPARC acts as a positive regulator on 
liver cancer progression [129, 130]. SPARC was found to be overexpressed in poorly 
differentiated HCC tissues compared with non-tumor livers [130]. It was also shown that the CpG 
islands in the SPARC promoter were hypo-methylated in HCC primary cells, which could 
explain increased SPARC levels in HCC cells [129]. Interestingly, SPARC is already detectable 
in fibrotic livers, suggesting that early mechanisms in cancer development are responsible for its 
overexpression [2, 131]. Studies in fibrotic livers together with the early study in HCC described 
an enrichment of SPARC in liver myofibroblast, which develop from liver stellate cell under 
inflammatory conditions [2, 130, 131]. Based on these data, SPARC secreted by myofibroblasts 
may induce liver cancer progression in a paracrine manner. My data further illustrate that liver 
cancer cells can also produce SPARC after disturbance of cell polarity and cytoplasmic 
enrichment of Scrib.  
 
6.6 Mislocalization of Scrib activates the AP1 family members ATF2 
and JunB 
Because cytoplasmic Scrib activated the AKT signaling pathway and cell invasion/migration-
associated genes, I asked, which transcription factors were responsible for the upregulation of 
ttarget genes induced by AKT pathway. It is known that the cytokine and growth factor-induced 
AP1 protein family is sensitive to extracellular stimuli and is activated by a variety of 
intracellular signaling pathways such as the JNK, ERK，p38 MAPK and AKT pathways [83]. I 
therefore hypothesized that AP1 family members might play a key role in the regulation of 
Scrib
P305L
-induced target genes via activation of AKT signaling. Indeed, my results demonstrated 
a higher activity of the AP1 proteins ATF2, JunB and c-Jun in Scrib
P305L 
cells, indicating that 
AP1 family members may act as important regulators of SPARC transcription in the HCC cells.  
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Next, the binding capacity of the AP1 proteins ATF2 and c-Jun at the SPARC promoter was 
analyzed. AP1 family members belong to leucine zipper-containing transcription factors, which 
binds to DNA as homo- or heterodimers. C-Jun is regarded as a central protein of AP1 family, 
which can interact with both ATFs and Fos subgroup members. These subgroups recognize 
distinct AP1 dimer binding site. Jun/Fos dimers bind to a 7 bp DNA palindromic sequence (5’-
TGAGTCA-3’ or 5’-TGACTCA-3’) [132], while ATF2 directly binds to a 8 bp palindrome (5’-
TGACGTCA-3’) [133]. Interestingly, different AP1 family members also facilitate distinct 
biological processes dependent on the composition of the dimer and the cell types [134, 135]. For 
example, c-Jun plays an important role in the regulation of cell cycle and apoptosis, which can be 
antagonized by JunB [134]. This suggests that the composition of AP1 dimers might affect the 
migratory response of HCC cells as illustrated by the different impacts of AP1 constituents on 
SPARC transcription.   
ChIP analyses performed in my thesis showed binding of both JunB and c-Jun at the SPARC 
promoter/enhancer region, which contains the described 7 bp binding motif (binding site 2) in 
cells overexpressing Scrib
P305L
. Notably, siRNA-mediated c-Jun inhibition revealed its negative 
regulatory impact on SPARC secretion, which illustrated that c-Jun may act as a repressor for 
SPARC expression. This was confirmed by a previous study showing that SPARC transcription 
was repressed by a viral homolog v-Jun in Drosophila melanogaster SL2 cells [136]. In contrast, 
JunB induced SPARC transcription, demonstrating that this AP-1 subunit served as a positive 
regulator in the used cell system. In addition to c-Jun and JunB, another AP1 protein ATF2, 
which showed the strongest impact on SPARC expression, bound to both potential binding sites 
in the SPARC promoter/enhancer. This result was in agreement with a large-scale promoter array 
analysis, which identified the interaction between ATF2 and SPARC promoter after cisplatin 
treatment [137], Notably, the second binding site was a 7-bp palindrome for Jun/Fos subgroups 
instead of ATF2, suggesting that the binding of ATF2 at the SPARC promoter/enhancer was 
probably due to other binding partners of the AP-1 dimers. 
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Figure 29: Summarizing scheme of how cytoplasmic Scrib induces tumor metastasis and EMT via 
activation of AKT pathway and AP1 transcriptional factors. (A) When Scrib locates to the plasma 
membrane, PHLPP1/PTEN inactivates the AKT signaling pathway in normal hepatocyte. (B) When Scrib 
locates to the cytoplasm, the AKT pathway is activated, which leads to a nuclear enrichment of AP1 
transcription factors ATF2 and JunB. (C) ATF2 and JunB bind to respective target gene promoters, and turn on 
target gene expression important for EMT and cell invasiveness. (D) SPARC is highly expressed by cells with 
cytoplasmic Scrib, which binds to membranous receptors on liver cancer cells and activates downstream 
signaling pathways involved in EMT and metastasis [125]. In (A) and (B), green colored areas indicate 
different subcellular regions of Scrib. In (D), SPARC is indicated in red, while other secreted factors are 
presented with grey.  
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6.7 Cytoplasmic Scrib co-operates with c-MYC in supporting liver 
tumor formation in mice 
In this study, I analyzed the oncogenic property of cytoplasmic Scrib in combination with the 
oncogene c-MYC, because c-MYC gene is located on chromosome 8q24.21 in close proximity to 
the Scrib gene on 8q24.3. This genomic region is known to be frequently amplified in in HCCs 
[86, 138]. Previous studies found that c-MYC amplification in HCC patients and induced tumor 
formation and progression via different mechanisms, including tumor cell proliferation, apoptosis 
and dedifferentiation [139, 140]. C-MYC promotes cell cycle progression through the activation 
of cell cycle proteins, e.g. cyclin D, cyclin dependent kinase (CDK) 4 and CDK6 [141]. In the 
liver, c-MYC expression synergized with AKT activation in promoting liver tumors after 
hydrodynamic gene delivery of both oncogenes [64]. I therefore asked if the co-delivery of c-
MYC and Scrib
WT/P305L
 isoforms (with Scrib
P305L
 leading to AKT activation) in mouse livers 
could affect c-MYC-dependent tumor formation in polarized hepatocytes.  
Indeed, my data in hydrodynamic tail-vein (HDTV) mouse model demonstrated that cytoplasmic 
Scrib cooperates with c-MYC in hepatocarcinogenesis already in early phases of tumor 
development. These results are in line with a study in breast cancer, which analyzed the effect of 
cytoplasmic Scrib in mammary glands [42]. This study detected frequent occurrence of 
hyperplastic lesions and development of malignant tumors after a long-term overexpression 
Scrib
P305L
 for two years [42]. The results generated in my thesis, show that the co-expression of 
cytoplasmic Scrib and c-MYC accelerates tumor formation in hepatocytes, since first solid cancer 
nodules were detectable after 6-8 week.  This rapid process is interesting since stable integration 
of the injected vectors is achieved in was about 2%-10% of all hepatocytes [64]. Importantly, 
HDTV-induced tumor models resemble the human situation of liver cancers, where tumor lesions 
are derived from single cells with several genomic alterations [64]. 
Most studies in vivo paid special attention to the activity of membranous Scrib instead of 
cytoplasmic Scrib in cancer development. Loss of membranous Scrib resulted in an EMT-
phenotype and tumor migration in Drosophila melanogaster [99]. Another study showed that 
membranous Scrib suppressed the oncogenic property of c-MYC in mammary tumor growth in a 
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subcutaneous transplantation mouse model [117]. In the recent HCC study, transgenic mice with 
genetic Scrib deletion spontaneously developed liver tumors [100]. Together, these data all 
illustrate the tumor-suppressive role of membranous Scrib in different independent tumor models. 
However, my thesis added a new level of how cytoplasmic Scrib supports tumor development in 
the liver. While mice expressing Scrib
WT
 and c-MYC showed few and small hepatic tumors, the 
Scrib
P305L
/c-MYC co-expression increased the number and size of macros- and microscopically 
detectable tumors. These findings, together with the results from other groups, indicate that Scrib 
facilitates tumor-suppressor or oncogenic functions depending on its subcellular localization.  
  
DISCUSSION 
 
102 
 
 
6.8 Potential application of Scrib in HCC prognosis and therapy 
Current studies revealed multiple functions of how polarity proteins are involved in tumor 
development under pathological conditions [33]. In my study, cytoplasmic localized Scrib 
showed an oncogenic property in promoting liver tumor progression, while other studies in HCC 
and breast cancer focused on the tumor-suppressive role of Scrib [100, 117]. According to this 
thesis, Scrib can be used as a biomarker for the classification of highly invasive HCC; however, 
the localization of Scrib has to be carefully analyzed in patients. In addition, some of Scrib target 
genes belong to EMT markers (e.g. CDH2 and MCAM). Together with Scrib, these EMT 
markers may help to define the subgroup of HCC patients with higher risk of 
migration/metastasis. 
From the therapeutic point of view, re-establishment of cell polarity with membranous Scrib 
localization could inhibit the progression of HCC. However, multiple factors contribute to the 
overexpression of Scrib (e.g. genomic alterations), while the direct molecular cause for 
cytoplasmic Scrib (mis-)localization is missing here. Current studies proposed an idea of re-
establishing cell polarity via the remodeling of liver ECM, however, irreversible fibrotic collagen 
deposition in livers makes this approach clinically not feasible, so far [2]. Because 
hyperactivation of AKT pathway was connected with the overexpression of cytoplasmic Scrib in 
this study, this supports the idea of personalized therapeutic approach in a subgroup of patients. 
These patients may benefit from an AKT/mTOR pathway-directed therapy with by FDA-
approved chemical compounds [142]. 
In this thesis, I also found that cytoplasmic Scrib induced signature gene expression (e.g., 
SPARC, TIMP1 and TIMP2) which was associated with remodeling of tumor microenvironment. 
These secreted factors are potential targets for the development of novel therapeutic approaches 
for the treatment of chronic liver disease and cancer [2]. Among these secreted factors, SPARC 
showed strongest effects on cell migration/invasion, which was confirmed by independent studies 
in different tumor entities [126, 127, 130]. So far, basic research for SPARC is still ongoing to 
define the relevant receptors and downstream signaling pathways. For example, the VCAM 
receptor, the platelet-derived growth factors (PDGF) receptor and stabilin have been identified as 
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potential SPARC-binding proteins. These receptors may differentially activate downstream 
pathways involved in, proliferation and migration of tumor cells but also vascular permeability 
and angiogenesis after SPARC uptake [125, 143, 144]. This thesis indicated that components 
targeting at SPARC or its receptors could be beneficial for a subgroup of HCC patients with early 
metastasis. Before this, a comprehensive understanding of the relevant SPARC receptors and 
their respective downstream signaling pathways is necessary. 
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